{"gene":"CXCL8","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1987,"finding":"CXCL8 (MDNCF/NAF/IL-8) was purified from LPS-stimulated human monocyte conditioned medium as a 7-kDa protein that acts as a potent and specific neutrophil chemoattractant, with activity comparable to fMet-Leu-Phe, but without chemotactic activity toward monocytes.","method":"Protein purification (anion-exchange, gel filtration, HPLC), chemotaxis assay, SDS-PAGE","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — purification to homogeneity with functional validation; two independent labs (Yoshimura/Matsushima and Walz/Baggiolini) reported essentially identical protein","pmids":["3480540","3322281"],"is_preprint":false},{"year":1988,"finding":"The cDNA for CXCL8 (MDNCF) was cloned from LPS-stimulated human monocytes, encoding a 99-aa precursor with a signal sequence; mature protein begins at Ser-28 (72 aa). MDNCF mRNA was induced >10-fold within 1 h by LPS, IL-1, or TNF, but not by IFN-γ, IFN-α, or IL-2.","method":"cDNA cloning, Northern blot, mRNA induction assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with functional mRNA induction mapping; foundational paper","pmids":["3260265"],"is_preprint":false},{"year":1989,"finding":"CXCL8 (NAP-1) is chemotactic not only for neutrophils but also for T lymphocytes; intradermal injection caused dose-dependent accumulation of both neutrophils and lymphocytes in rats.","method":"In vitro chemotaxis assay, in vivo rat injection model","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — direct in vitro and in vivo functional demonstration with purified/recombinant protein","pmids":["2648569"],"is_preprint":false},{"year":1989,"finding":"Two distinct CXCL8-binding polypeptides were identified on human neutrophils (~67 kDa and ~59 kDa) by chemical cross-linking; Scatchard analysis revealed ~20,000 high-affinity receptors per cell (Kd ~8×10⁻¹⁰ M). These receptors are distinct from IL-1α, TNF-α, fMLP, C5a, LTB4, and PAF receptors.","method":"¹²⁵I-ligand binding, Scatchard analysis, chemical cross-linking, SDS-PAGE","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — direct binding and cross-linking identifying receptor polypeptides with Kd determination","pmids":["2647892"],"is_preprint":false},{"year":1989,"finding":"The CXCL8 gene (MDNCF/IL-8) consists of 4 exons and 3 introns. The 5'-flanking region contains potential binding sites for AP-1, AP-2, IRF-1, HNF-1, glucocorticoid response element, and heat shock element, providing a molecular basis for its transcriptional regulation by inflammatory stimuli and suppression by glucocorticoids.","method":"Genomic DNA cloning and sequencing, promoter analysis","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 1 — complete genomic structure determination with regulatory element identification","pmids":["2663993"],"is_preprint":false},{"year":1990,"finding":"The three-dimensional solution structure of the CXCL8 dimer was solved by NMR spectroscopy: two antiparallel α-helices (~24 Å long, separated by ~14 Å) lie on a six-stranded antiparallel β-sheet platform; the two C-terminal α-helices were proposed to form the receptor-binding site.","method":"NMR spectroscopy, hybrid distance geometry-dynamical simulated annealing (1880 distance restraints, 362 torsion angle restraints)","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — high-resolution NMR structure with extensive restraints and precise atomic coordinates","pmids":["2184886"],"is_preprint":false},{"year":1990,"finding":"The CXCL8 gene maps to human chromosome 4q12–q21, co-localizing with platelet factor 4, MGSA, and IFN-γ-induced factor—all members of the platelet factor 4 gene superfamily—establishing CXCL8 as part of this gene cluster.","method":"Human-rodent somatic cell hybrid panel, in situ hybridization, RFLP analysis","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 — direct chromosomal mapping using two orthogonal methods","pmids":["1967588"],"is_preprint":false},{"year":1990,"finding":"The CXCL8 coding region consists of 4 exons and 3 introns and is homogeneous across human cell types; the primary translation product carries an N-terminal AVLPR sequence (LUCT form) that is subsequently truncated to generate the mature form without this extension.","method":"PCR from genomic DNA of multiple cell types, sequencing","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2 — genomic PCR across multiple cell sources confirming coding region homogeneity and identifying N-terminal processing","pmids":["2200751"],"is_preprint":false},{"year":1991,"finding":"A cDNA encoding the CXCL8 receptor (IL-8RA/CXCR1) was cloned from human neutrophils; the protein is a G protein-coupled receptor (GPCR) 29% identical to fMLP and C5a receptors. Transfected mammalian cells bound IL-8 with high affinity and responded with transient calcium mobilization, establishing CXCR1 as a functional GPCR for CXCL8.","method":"cDNA expression cloning, radioligand binding, calcium mobilization assay in transfected cells","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — molecular cloning with functional reconstitution in heterologous cells","pmids":["1840701"],"is_preprint":false},{"year":1992,"finding":"Macrophage-derived CXCL8 (IL-8) is potently angiogenic: recombinant IL-8 induced endothelial cell proliferation and chemotaxis in vitro and angiogenesis in the rat cornea in vivo. Anti-IL-8 antibodies blocked angiogenic activity of LPS-stimulated monocyte conditioned medium, and an IL-8 antisense oligonucleotide specifically blocked monocyte-induced angiogenic activity.","method":"Rat cornea implant angiogenesis assay, HUVEC proliferation and chemotaxis assay, neutralizing antibody blockade, antisense oligonucleotide","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (in vivo cornea, in vitro cell assays, antibody neutralization, antisense) demonstrating angiogenic function","pmids":["1281554"],"is_preprint":false},{"year":1992,"finding":"CXCL8 activates neutrophils inducing chemotaxis, exocytosis, and the respiratory burst; it is produced by phagocytes and mesenchymal cells in response to IL-1 or TNF stimulation.","method":"Neutrophil functional assays (chemotaxis, exocytosis, oxidative burst), cell stimulation","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — direct functional assays in primary neutrophils, replicated across multiple groups","pmids":["1639201"],"is_preprint":false},{"year":1996,"finding":"CXCL8 (IL-8) signals through two receptor subtypes with distinct selectivity: IL8RA (CXCR1) is highly selective for IL-8 (EC50 ~4 nM) with weak responses to other ELR+ CXC chemokines; IL8RB (CXCR2) is promiscuous, responding potently to GROα/β/γ, NAP-2, ENA-78, and IL-8 (EC50 1–11 nM). Receptor selectivity was determined by calcium flux in transfected HEK293 cells and competitive radioligand binding.","method":"Calcium flux assay in HEK293 cells transfected with CXCR1 or CXCR2, competitive radioligand binding with ¹²⁵I-labeled chemokines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — quantitative pharmacological characterization in defined reconstituted system with multiple ligands and binding assays","pmids":["8702798"],"is_preprint":false},{"year":1997,"finding":"CXCL8 is transcytosed across venular endothelial cells from the abluminal to luminal surface, where it is presented on EC membrane projections to adherent leukocytes. The intact C-terminus of IL-8 (its glycosaminoglycan-binding/immobilization domain) is required for EC binding, transcytosis, and in vivo pro-emigratory activity.","method":"Electron microscopy of transcytosis, C-terminal deletion mutants, in vivo leukocyte emigration assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — direct structural visualization by EM plus functional mutagenesis and in vivo validation","pmids":["9363947"],"is_preprint":false},{"year":2000,"finding":"Neutrophil gelatinase B (MMP-9) cleaves full-length CXCL8(1-77) to generate CXCL8(7-77), which is 10–27-fold more potent in neutrophil activation (Ca²⁺ flux, gelatinase B secretion, chemotaxis), correlating with enhanced binding to neutrophils and increased CXCR1 signaling. This represents a positive feedback loop between MMP-9 and IL-8. In contrast, MMP-9 degrades CTAP-III, PF-4, and GRO-α but leaves RANTES and MCP-2 intact.","method":"In vitro MMP-9 cleavage, neutrophil Ca²⁺ signaling, degranulation assay, chemotaxis assay, receptor binding, CXCR1/CXCR2-transfected cell lines","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution of proteolytic processing linked to receptor-specific functional potentiation via multiple orthogonal assays","pmids":["11023497"],"is_preprint":false},{"year":2002,"finding":"CXCL8 (IL-8) elicits angiogenic responses (stress fiber assembly, chemotaxis, ERK1/2 phosphorylation, tube formation) in human intestinal microvascular endothelial cells (HIMEC) specifically through CXCR2 (not CXCR1, which is absent on HIMEC). ERK1/2 and PI3K inhibitors abrogated these responses.","method":"RT-PCR, immunohistochemistry, flow cytometry, Western blot, neutralizing antibody, pharmacological inhibition, proliferation/chemotaxis assays, tube formation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific attribution using neutralizing antibodies plus signaling pathway dissection with multiple inhibitors in primary cells","pmids":["12496258"],"is_preprint":false},{"year":2003,"finding":"IL-8 directly promotes endothelial cell survival, proliferation, and MMP-2/MMP-9 production via CXCR1- and CXCR2-expressing endothelial cells. IL-8 inhibited apoptosis and enhanced Bcl-xL:Bcl-xS and Bcl-2:Bax ratios in HUVECs, and neutralizing anti-IL-8 antibody blocked capillary tube formation.","method":"CXCR1/CXCR2 expression analysis (RT-PCR, protein), proliferation assay, apoptosis assay, anti-apoptotic gene expression, MMP production, tube formation assay, neutralizing antibody","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with neutralization in primary endothelial cells","pmids":["12626597"],"is_preprint":false},{"year":2003,"finding":"CXCL8 (IL-8) and GROα/CXCL1 induce chondrocyte hypertrophic differentiation (type X collagen, MMP-13, alkaline phosphatase expression, matrix calcification) via CXCR1 and CXCR2 through p38 MAPK signaling. Transglutaminase 2 (TG2) is essential for CXCL8-induced hypertrophy and calcification, acting downstream of p38.","method":"Primary human/bovine/mouse chondrocyte cultures, CXCR1/CXCR2 expression confirmation, p38 inhibition, TG2 knockout mouse chondrocytes, gene/activity assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 — genetic (TG2 KO) plus pharmacological (p38 inhibitor) epistasis in primary cells with multiple differentiation markers","pmids":["14530367"],"is_preprint":false},{"year":2004,"finding":"Oncogenic Ras signaling drives transcriptional upregulation of CXCL8 in tumor cells, and Ras-dependent CXCL8 secretion is required for tumor-associated inflammation and neovascularization in vivo. Ectopic CXCL8 expression rescued angiogenesis in Ras-signaling-impaired tumor xenografts.","method":"Tumor xenograft model, Ras signaling manipulation, CXCL8 reporter assays, in vivo angiogenesis assessment","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic rescue experiment identifying CXCL8 as a downstream transcriptional target of Ras required for tumor angiogenesis","pmids":["15542429"],"is_preprint":false},{"year":2004,"finding":"CXCL8 (IL-8) acts as an autocrine growth factor for NSCLC lung cancer cells expressing both IL-8 and CXCR1/CXCR2; the mitogenic function is mediated predominantly by CXCR1 (not CXCR2), as shown by selective receptor-neutralizing antibodies. In SCLC cells (expressing receptors but not producing IL-8), exogenous IL-8 stimulated proliferation in a dose-dependent manner.","method":"Anti-IL-8 neutralizing antibody, anti-CXCR1 and anti-CXCR2 antibodies, MTT proliferation assay, PCNA analysis, cell cycle analysis","journal":"British journal of cancer","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific functional attribution using selective neutralizing antibodies in multiple cell lines with multiple proliferation readouts","pmids":["15545974"],"is_preprint":false},{"year":2005,"finding":"2-Arylpropionic acid compounds (including repertaxin) are noncompetitive CXCL8 inhibitors that bind an allosteric site within the transmembrane (TM) region of CXCR1. The binding site was confirmed by alanine scanning mutagenesis and photoaffinity labeling of CXCR1.","method":"Molecular modeling, alanine scanning mutagenesis of CXCR1, photoaffinity labeling, PMN chemotaxis inhibition assay","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus covalent photolabeling identifying receptor binding site; orthogonal methods","pmids":["15974585"],"is_preprint":false},{"year":2006,"finding":"Thrombin induces IL-8/CXCL8 expression in human lung epithelial cells (A549) through PAR1 and PAR4 receptors via a phosphoinositide-PLC/PKCα/c-Src/IKKαβ signaling cascade leading to NF-κB activation. PKCα, c-Src, and IKKαβ form a physical complex, and the CXCL8 NF-κB κB site is required for thrombin-induced transcription.","method":"Dominant-negative mutants, pharmacological inhibitors (U73122, Ro-32-0432, Bay 117082), κB-site luciferase reporter, Co-immunoprecipitation (PKCα/c-Src/IKKαβ complex), kinase activity assays, NF-κB EMSA","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 — pathway dissected by dominant-negatives, multiple pharmacological inhibitors, Co-IP of complex, and promoter reporter with site-directed mutation","pmids":["16920985"],"is_preprint":false},{"year":2006,"finding":"Murine CXCR1 is a functional receptor that binds and responds to human IL-8/CXCL8 and mouse/human GCP-2/CXCL6, but not to CXCR2-selective ligands (ENA-78, NAP-2, GRO-α/β/γ, CINC-1-3). Functional characterization included GTPγS exchange and chemotaxis of mCXCR1-transfected cells.","method":"Receptor transfection, radioligand binding, GTPγS exchange assay, chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted receptor pharmacology in transfected cells with multiple functional readouts","pmids":["17197447"],"is_preprint":false},{"year":2008,"finding":"Peptidylarginine deiminase (PAD) citrullinates CXCL8 at Arg5, generating CXCL8(1-77)Cit5. This modification: (i) reduces GAG affinity, (ii) reduces CXCR2-dependent Ca²⁺ signaling and ERK1/2 phosphorylation, (iii) confers resistance to thrombin/plasmin-dependent N-terminal processing to the more potent CXCL8(6-77) form, and (iv) abolishes neutrophil recruitment in vivo despite retained in vitro chemotactic activity.","method":"PAD citrullination in vitro, mass spectrometry identification of Cit5 on natural leukocyte CXCL8, GAG binding assay, Ca²⁺ signaling, ERK phosphorylation, thrombin/plasmin cleavage assay, in vivo peritoneal neutrophil recruitment, rabbit cornea angiogenesis assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — PTM identified on natural protein, reconstituted biochemically, validated across receptor signaling, proteolytic processing resistance, and in vivo animal models","pmids":["18710930"],"is_preprint":false},{"year":2009,"finding":"CXCL8 promotes invasiveness and angiogenesis in pancreatic cancer through HUVEC proliferation/invasion and tube formation via paracrine signaling. Fibroblast-derived CXCL12 enhances CXCL8 production by PaCa cells, and PaCa-derived CXCL8 enhances CXCL12 production in fibroblasts, establishing a cooperative tumor-stromal loop.","method":"Co-culture systems, ELISA, Matrigel invasion assay, MTS proliferation assay, HUVEC tube formation assay, CXCR4/CXCR2 expression by RT-PCR","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 — co-culture mechanistic experiments demonstrating bi-directional paracrine loop, single lab","pmids":["19035451"],"is_preprint":false},{"year":2009,"finding":"Cell surface-bound IL-1α is an upstream regulator of senescence-associated IL-8/CXCL8 secretion in human fibroblasts. IL-1 receptor antagonist, neutralizing IL-1α antibodies, and IL-1α RNAi all suppressed senescence-associated IL-8 secretion. This pathway operates through IL-1R/IRAK1 → NF-κB/C/EBPβ → IL-8 transcription.","method":"RNAi knockdown, neutralizing antibodies, IL-1R antagonist, NF-κB DNA-binding assay, IRAK1 depletion, conditioned medium tumor invasion assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genetic and pharmacological perturbations defining upstream regulator of CXCL8 in senescence","pmids":["19805069"],"is_preprint":false},{"year":2009,"finding":"MiR-146a/b are induced during cellular senescence and function as negative regulators of senescence-associated IL-6 and IL-8 secretion by downregulating IRAK1, a key IL-1R signaling component. Ectopic miR-146a/b expression in primary fibroblasts suppressed IL-6 and IL-8 secretion.","method":"miRNA profiling, ectopic miRNA expression, IRAK1 knockdown, ELISA for IL-6/IL-8, IL-1α neutralizing antibodies","journal":"Aging","confidence":"High","confidence_rationale":"Tier 2 — ectopic gain-of-function and epistasis (IL-1α blockade abolishing miR-146a/b and IL-8) with mechanistic IRAK1 linkage","pmids":["20148189"],"is_preprint":false},{"year":2011,"finding":"Glycosaminoglycan-mediated CXCL8 binding to endothelial cells induces downstream signaling (identified syndecan-4/SDC4 as a potential proteoglycan co-receptor) and changes in cytoskeletal organization proteins (Zyxin, Caldesmon), demonstrating a GAG-dependent signaling pathway distinct from CXCR1/CXCR2-mediated neutrophil signaling.","method":"Gene array, RT-PCR, flow cytometry (SDC4), enzymatic GAG depolymerization (heparinase III, chondroitinase ABC), proteomic analysis of endothelial protein expression changes","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, proteomics plus enzymatic depletion, moderate mechanistic depth","pmids":["29207576"],"is_preprint":false},{"year":2011,"finding":"CXCL8 promotes endothelial cell migration through a heparan sulfate (HS)-dependent mechanism: removal of HS by heparinase III abolished CXCL8-induced wound healing, suppressed CXCL8-upregulated Cdc42, Rac1, and RhoA activity, and blocked actin polymerization, polarization, and stress fiber formation.","method":"Wound healing assay, heparinase III enzymatic HS removal, Rho GTPase activity assays (Cdc42, Rac1, RhoA), actin cytoskeleton imaging","journal":"PeerJ","confidence":"Medium","confidence_rationale":"Tier 2 — enzymatic HS removal with defined molecular readouts of Rho GTPase and cytoskeletal responses; single lab","pmids":["26870616"],"is_preprint":false},{"year":2014,"finding":"TSG-6 directly binds CXCL8 at its glycosaminoglycan-binding site (Kd ~25 nM), antagonizing CXCL8 association with heparin, impairing CXCL8 binding to cell-surface GAGs, blocking CXCL8 transcytosis across endothelial monolayers, and suppressing CXCL8-mediated neutrophil chemotaxis. TSG-6 is identified as the first soluble mammalian chemokine-binding protein.","method":"SPR binding (Kd measurement), heparin competition assay, transendothelial migration assay, cell-surface GAG binding assay, transwell chemotaxis assay","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 — direct binding affinity measurement plus multiple functional assays demonstrating mechanism of inhibition","pmids":["24501198"],"is_preprint":false},{"year":2016,"finding":"MiR-146a limits CXCL8/CXCL1-driven inflammation after renal ischemia-reperfusion injury via suppression of IRAK1. In miR-146a-/- mice, IRI caused more tubular injury, inflammatory infiltrates, and fibrosis; overexpression/knockdown of miR-146a in tubular cells inversely regulated IRAK1 and CXCL8/CXCL1. CXCL8/CXCL1 signaling inhibition rescued the miR-146a-/- phenotype.","method":"miR-146a knockout mice, unilateral IRI model, in vitro miRNA overexpression/knockdown, CXCL8 pathway inhibition rescue, IRAK1 expression analysis","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus pharmacological rescue with CXCL8 pathway inhibition; in vivo and in vitro orthogonal approaches","pmids":["27444565"],"is_preprint":false},{"year":2017,"finding":"ZO-1 (zonula occludens-1), when relocalized from tight junctions to the cytonuclear compartment, activates CXCL8/IL-8 transcription through a specific 173-bp promoter region containing a critical NF-κB (p65) site. ZO-1 overexpression promotes angiogenesis in ex vivo and in vivo assays, and NSCLC with cytonuclear ZO-1 was significantly more angiogenic.","method":"siRNA/cDNA transfection, luciferase reporter assay with promoter truncations and κB site mutation, p65 siRNA, IκBα/p65 phosphorylation analysis, ex vivo/in vivo angiogenesis assays","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"High","confidence_rationale":"Tier 2 — promoter dissection with site-directed mutation plus genetic epistasis (p65 knockdown) and functional angiogenesis assays","pmids":["28057697"],"is_preprint":false},{"year":2018,"finding":"Citrullination of CXCL8 at Arg5 and N-terminal truncation to CXCL8(6-77) differentially modulate CXCR1 and CXCR2 internalization, Gαi-dependent signaling, and β-arrestin 1/2 recruitment. CXCL8(6-77) shows enhanced β-arrestin 2 recruitment to both CXCR1 and CXCR2; [Cit5]CXCL8 enhances β-arrestin 2 recruitment specifically to CXCR2. Neither modification acts as a biased agonist (no shift in G-protein vs. β-arrestin preference).","method":"Synthetic CXCL8 variants, neutrophil receptor internalization assays, Gαi signaling (HTRF), β-arrestin 1/2 recruitment assays (BRET)","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 — chemically defined synthetic variants with quantitative receptor signaling assays distinguishing G-protein and β-arrestin pathways","pmids":["30486423"],"is_preprint":false},{"year":2019,"finding":"Evasin-3 (a tick salivary protein) binds CXCL8 and disrupts both the GAG-binding site and the CXCR2 interaction surface of CXCL8, as revealed by solution NMR. Synthetic Evasin-3 variants (linear and cyclic peptides) bound CXCL8 with Kd ~13–27 nM and effectively inhibited CXCL8-induced PMN migration.","method":"Solution NMR structure of CXCL8–Evasin-3 complex, SPR binding assays, PMN chemotaxis inhibition assay, solid-phase peptide synthesis of truncated variants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structure of protein-protein complex with SPR quantification and functional validation","pmids":["31235521"],"is_preprint":false},{"year":2019,"finding":"Notch1 activation in triple-negative breast cancer cells, driven by contact with MSCs or CAFs in a TNFα/IL-1β-inflammatory context, leads to NF-κB (p65) activation which in turn upregulates CXCL8 production in TNBC cells. Notch1 siRNA and DAPT (γ-secretase inhibitor) suppressed contact-dependent CXCL8 induction and TNBC migration/invasion.","method":"Notch1 siRNA, CRISPR/Cas9 p65 knockdown, CXCL8 siRNA, γ-secretase inhibitor (DAPT), co-culture contact vs. non-contact conditions, migration/invasion assays","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic tools (siRNA, CRISPR) and pharmacological inhibitor with defined functional readouts in structured co-culture system","pmids":["31105691"],"is_preprint":false},{"year":2020,"finding":"N-terminal truncation of CXCL8 to generate CXCL8(9-77) potentiates actin polymerization in neutrophils and significantly enhances in vivo neutrophil recruitment to the mouse peritoneal cavity compared to CXCL8(6-77), while Ca²⁺ signaling and in vitro chemotaxis potency are comparable between truncated forms.","method":"Actin polymerization assay, Ca²⁺ signaling, in vitro chemotaxis, in vivo peritoneal recruitment model, neutrophil surface marker assays (CD62L, CD11a/b, CD15), degranulation assay, phagocytosis assay","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — direct comparison of defined natural truncation variants across multiple assays including in vivo model","pmids":["32272490"],"is_preprint":false},{"year":2022,"finding":"Thrombin activates a DCLK1/RhoA/YAP signaling cascade in lung epithelial cells to induce CXCL8 expression. DCLK1 (activated via ERK) activates RhoA and promotes YAP dephosphorylation at Ser127 and nuclear translocation; nuclear YAP forms a complex with p65 (NF-κB) and both are recruited to the NF-κB site on the CXCL8 promoter. DCLK1 siRNA blocked RhoA, YAP activation, κB-luciferase activity, and p65/YAP promoter binding.","method":"siRNA (DCLK1, YAP), pharmacological inhibitors (DCLK1, ERK), ChIP assay (YAP and p65 at IL-8 promoter), luciferase reporter, Western blot (pSer127-YAP), immunofluorescence (YAP localization), ELISA, in vivo asthma model (OVA-induced)","journal":"Journal of biomedical science","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirming promoter occupancy plus multiple genetic/pharmacological epistasis experiments in vitro and in vivo validation","pmids":["36369000"],"is_preprint":false},{"year":2023,"finding":"CXCL8 maintains the mesenchymal state of glioblastoma stem cells (GSCs) via cell-intrinsic PI3K/AKT and NF-κB signaling, and drives M2-like TAM polarization through a cell-extrinsic CXCR2-JAK2/STAT3 axis. Combined genetic/pharmacological inhibition of these dual pathways suppressed GBM tumor growth and prolonged survival in orthotopic xenograft models.","method":"Patient-derived GSC cultures, xenograft model, multi-omics RNA-seq, genetic inhibition (CXCL8/CXCR2 knockdown), small molecule inhibitors, TAM polarization assays, PI3K/AKT and JAK2/STAT3 pathway analysis","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","confidence":"High","confidence_rationale":"Tier 2 — dual cell-intrinsic and extrinsic pathway dissection with genetic and pharmacological tools, validated in vivo","pmids":["37439870"],"is_preprint":false},{"year":2023,"finding":"CXCL8/CXCR2 signaling mediates bone marrow fibrosis in myelofibrosis: hematopoietic stem/progenitor cells from MF patients display enriched CXCL8/CXCR2 signatures. Genetic deletion of Cxcr2 in a murine MF model abrogated fibrosis and extended survival; pharmacological CXCR1/2 inhibition attenuated fibrosis and synergized with JAK inhibitor therapy.","method":"Single-cell transcriptomics, cytokine secretion studies, Cxcr2 genetic knockout in adoptive transfer model, pharmacological CXCR1/2 inhibition, in vitro HSC proliferation assay with CXCL8","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic KO in disease model plus pharmacological synergy study with mechanistic single-cell resolution","pmids":["36800567"],"is_preprint":false}],"current_model":"CXCL8 (IL-8) is a dimeric CXC chemokine (NMR structure resolved) secreted by monocytes, macrophages, and epithelial cells in response to IL-1, TNF, LPS, and Ras oncogene signaling via NF-κB and related transcription factors; it is processed from a 99-aa precursor, and its activity is fine-tuned by N-terminal proteolytic truncation (MMP-9 generating the more potent CXCL8(7-77)) and citrullination at Arg5 by PAD, which reduces GAG binding and CXCR2 signaling; mature CXCL8 is transcytosed across venular endothelium for luminal presentation via its GAG-binding C-terminus, and signals through two GPCRs—CXCR1 (IL-8-selective) and CXCR2 (promiscuous)—via Gαi/Ca²⁺, PI3K/AKT, ERK, and β-arrestin pathways to drive neutrophil chemotaxis, actin polymerization, degranulation, and respiratory burst; additionally, CXCL8 promotes angiogenesis by directly stimulating endothelial cell survival, proliferation, MMP-2/9 production, and tube formation predominantly through CXCR2, and mediates tumor progression through autocrine growth factor activity, cancer stem cell maintenance (PI3K/AKT and NF-κB), and immunosuppressive TAM polarization (CXCR2-JAK2/STAT3)."},"narrative":{"teleology":[{"year":1987,"claim":"The discovery of CXCL8 as a distinct neutrophil-specific chemoattractant produced by LPS-stimulated monocytes established it as a novel mediator separate from complement factors and lipid mediators, answering the question of what soluble factor selectively recruits neutrophils during inflammation.","evidence":"Purification to homogeneity from monocyte conditioned medium with chemotaxis assays showing neutrophil but not monocyte activity","pmids":["3480540","3322281"],"confidence":"High","gaps":["Receptor identity unknown","In vivo relevance not yet established","Gene structure not yet determined"]},{"year":1988,"claim":"Molecular cloning of the CXCL8 cDNA revealed a 99-amino-acid precursor with signal peptide processing and rapid mRNA induction by IL-1, TNF, and LPS but not interferons, establishing CXCL8 as an immediate-early inflammatory gene with defined transcriptional inducers.","evidence":"cDNA cloning from LPS-stimulated monocytes with Northern blot kinetics of mRNA induction","pmids":["3260265"],"confidence":"High","gaps":["Promoter elements responsible for inducibility not yet mapped","Post-translational processing details unknown"]},{"year":1989,"claim":"Identification of high-affinity CXCL8-binding receptors on neutrophils (~20,000 sites/cell, Kd ~0.8 nM) distinct from all known chemoattractant receptors, together with demonstration that CXCL8 also attracts T lymphocytes in vivo, expanded the target cell repertoire and established receptor-mediated signaling as the basis for CXCL8 activity.","evidence":"Radioligand binding, Scatchard analysis, chemical cross-linking on neutrophils; in vivo rat intradermal injection with lymphocyte/neutrophil quantification","pmids":["2647892","2648569"],"confidence":"High","gaps":["Molecular identity of receptors unknown","Signaling pathways downstream of binding not characterized"]},{"year":1990,"claim":"Determination of the CXCL8 dimer structure by NMR and mapping of the gene to chromosome 4q12–q21 within the CXC chemokine cluster provided the structural and genomic framework, revealing the antiparallel α-helix/β-sheet architecture and its evolutionary relationship to the PF4 superfamily.","evidence":"NMR spectroscopy with 1880 distance restraints; somatic cell hybrid mapping and in situ hybridization","pmids":["2184886","1967588"],"confidence":"High","gaps":["Monomer vs. dimer activity not resolved","Structure of receptor-bound CXCL8 unknown"]},{"year":1991,"claim":"Cloning of CXCR1 (IL-8RA) as a GPCR with high-affinity IL-8 binding and calcium mobilization in transfected cells answered the fundamental question of receptor identity and established the GPCR/Gαi signaling paradigm for CXCL8.","evidence":"Expression cloning from neutrophil cDNA library, radioligand binding and calcium flux in transfected mammalian cells","pmids":["1840701"],"confidence":"High","gaps":["Second receptor (CXCR2) selectivity profile not yet defined","Downstream signaling cascades not mapped"]},{"year":1992,"claim":"The demonstration that CXCL8 is a potent angiogenic factor—inducing endothelial proliferation, chemotaxis, and neovascularization in the rat cornea—revealed a second major biological function beyond neutrophil chemotaxis.","evidence":"Rat cornea angiogenesis assay, HUVEC proliferation/chemotaxis, anti-IL-8 antibody and antisense oligonucleotide blockade","pmids":["1281554"],"confidence":"High","gaps":["Receptor subtype mediating angiogenesis unknown","Signaling pathways in endothelial cells not defined"]},{"year":1996,"claim":"Pharmacological characterization of CXCR1 vs. CXCR2 selectivity resolved how CXCL8 signals through two receptors with distinct ligand profiles: CXCR1 is IL-8-selective while CXCR2 is promiscuous for ELR+ CXC chemokines.","evidence":"Quantitative calcium flux and competitive radioligand binding in HEK293 cells transfected with individual receptors","pmids":["8702798"],"confidence":"High","gaps":["Receptor subtype-specific downstream effectors not dissected","In vivo receptor subtype contributions unclear"]},{"year":1997,"claim":"Discovery that CXCL8 is transcytosed across venular endothelium and presented luminally via its GAG-binding C-terminus resolved how a subendothelially produced chemokine reaches and activates intravascular leukocytes, establishing the transcytosis–immobilization paradigm for chemokine biology.","evidence":"Electron microscopy of transcytosis, C-terminal deletion mutants lacking GAG binding, in vivo leukocyte emigration assay","pmids":["9363947"],"confidence":"High","gaps":["Vesicular machinery for transcytosis unidentified","Proteoglycan identity on luminal surface unknown"]},{"year":2000,"claim":"Identification of MMP-9-mediated N-terminal truncation generating the 10–27-fold more potent CXCL8(7-77) established a positive feedback amplification loop at inflammatory sites where neutrophil degranulation potentiates the chemokine that recruited them.","evidence":"In vitro MMP-9 cleavage with neutrophil Ca²⁺ flux, chemotaxis, degranulation, and receptor binding assays on CXCR1/CXCR2-transfected cells","pmids":["11023497"],"confidence":"High","gaps":["In vivo ratio of CXCL8 proteoforms during inflammation not quantified","Other proteases generating truncated forms not systematically assessed"]},{"year":2002,"claim":"Attribution of CXCL8-driven angiogenesis specifically to CXCR2 (with ERK1/2 and PI3K as required effectors) in primary microvascular endothelial cells resolved which receptor subtype mediates the pro-angiogenic program.","evidence":"HIMEC expressing CXCR2 but not CXCR1; neutralizing antibodies, ERK and PI3K inhibitors blocking tube formation and chemotaxis","pmids":["12496258"],"confidence":"High","gaps":["CXCR1 contribution to angiogenesis in other vascular beds not excluded","Transcriptional targets downstream of ERK/PI3K in endothelial cells not mapped"]},{"year":2004,"claim":"Demonstration that oncogenic Ras drives CXCL8 transcription and that CXCL8 is required for Ras-dependent tumor angiogenesis and inflammation repositioned CXCL8 as a critical effector of oncogene-driven tumor progression, while receptor-specific studies showed CXCR1-mediated autocrine growth in lung cancer.","evidence":"Tumor xenograft rescue with ectopic CXCL8 in Ras-impaired cells; selective CXCR1/CXCR2 neutralizing antibodies in NSCLC proliferation assays","pmids":["15542429","15545974"],"confidence":"High","gaps":["Transcription factor(s) linking Ras to CXCL8 promoter not fully defined","Autocrine loop contribution vs. paracrine angiogenic role not separated in vivo"]},{"year":2008,"claim":"Discovery that PAD-mediated citrullination at Arg5 dampens GAG binding, CXCR2 signaling, and in vivo neutrophil recruitment—while also blocking N-terminal truncation to more active forms—revealed a post-translational brake that fine-tunes CXCL8 bioactivity at inflamed sites.","evidence":"PAD citrullination in vitro, mass spectrometry of natural leukocyte CXCL8, GAG/receptor signaling assays, thrombin/plasmin resistance, in vivo peritoneal recruitment","pmids":["18710930"],"confidence":"High","gaps":["Physiological conditions controlling PAD access to CXCL8 unknown","Relative abundance of citrullinated vs. unmodified CXCL8 in human disease tissues not quantified"]},{"year":2009,"claim":"Identification of surface-bound IL-1α/IRAK1/NF-κB as the upstream cascade driving senescence-associated CXCL8 secretion, negatively regulated by miR-146a/b targeting IRAK1, linked CXCL8 to the senescence-associated secretory phenotype and its regulation by a microRNA feedback loop.","evidence":"IL-1Rα, neutralizing antibodies, and IL-1α/IRAK1 RNAi suppressed senescence-associated IL-8; ectopic miR-146a/b suppressed IL-8 via IRAK1 depletion","pmids":["19805069","20148189"],"confidence":"High","gaps":["Other miRNAs directly targeting CXCL8 mRNA not systematically evaluated","In vivo relevance of miR-146a–CXCL8 axis in aging tissues not established at this time"]},{"year":2014,"claim":"Identification of TSG-6 as a soluble antagonist that binds the CXCL8 GAG-binding site with nanomolar affinity and blocks transcytosis and neutrophil chemotaxis revealed a physiological counter-regulatory mechanism for CXCL8 presentation and activity.","evidence":"SPR (Kd ~25 nM), heparin competition, transendothelial transcytosis blockade, chemotaxis inhibition","pmids":["24501198"],"confidence":"High","gaps":["In vivo relevance of TSG-6-CXCL8 interaction in resolving inflammation not tested","Whether TSG-6 antagonizes other CXC chemokines not systematically assessed"]},{"year":2018,"claim":"Quantitative dissection of how citrullination and N-terminal truncation modulate Gαi signaling vs. β-arrestin recruitment to CXCR1 and CXCR2 showed that these post-translational modifications alter signaling magnitude at each receptor without inducing biased agonism, refining the model of CXCL8 proteoform-specific signaling.","evidence":"Synthetic CXCL8 variants tested by HTRF (Gαi) and BRET (β-arrestin 1/2) with quantitative dose-response curves","pmids":["30486423"],"confidence":"High","gaps":["Functional consequences of β-arrestin recruitment differences in vivo unknown","Whether additional post-translational modifications (e.g. oxidation) alter bias not tested"]},{"year":2022,"claim":"Mapping of a DCLK1/RhoA/YAP–p65 transcriptional cascade driving CXCL8 expression in thrombin-stimulated epithelial cells, with ChIP confirming YAP and p65 co-occupancy at the CXCL8 NF-κB site, revealed a non-canonical mechanotransduction input to CXCL8 transcription.","evidence":"ChIP of YAP/p65 at IL-8 promoter, DCLK1 and YAP siRNA epistasis, κB-luciferase reporter, in vivo asthma model validation","pmids":["36369000"],"confidence":"High","gaps":["Whether YAP-p65 co-regulation of CXCL8 operates in cell types beyond lung epithelium not tested","Contribution relative to canonical NF-κB activation unknown"]},{"year":2023,"claim":"Demonstration that CXCL8 operates through dual cell-intrinsic (PI3K/AKT, NF-κB maintaining cancer stemness) and cell-extrinsic (CXCR2–JAK2/STAT3 polarizing immunosuppressive TAMs) axes in glioblastoma, and that CXCL8/CXCR2 signaling drives bone marrow fibrosis in myelofibrosis, broadened the disease-relevant roles of CXCL8 beyond solid tumor angiogenesis.","evidence":"Patient-derived GSC xenografts with CXCL8/CXCR2 knockdown and combined pathway inhibition; Cxcr2 KO in murine MF model with pharmacological CXCR1/2 inhibition synergizing with JAK inhibitor","pmids":["37439870","36800567"],"confidence":"High","gaps":["Relative contributions of autocrine vs. paracrine CXCL8 in GBM microenvironment not fully resolved","Whether CXCR1 contributes to MF pathology independently of CXCR2 not tested","Clinical efficacy of CXCR2 inhibition in myelofibrosis awaits trial data"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CXCL8 binding to CXCR1 vs. CXCR2 at atomic resolution, the identity of the vesicular machinery mediating CXCL8 transcytosis, the quantitative proteoform landscape of CXCL8 at inflammatory sites in vivo, and whether therapeutic CXCL8 neutralization or receptor blockade can be safely deployed without compromising host defense.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of CXCL8–CXCR1 or CXCL8–CXCR2 complex available","Transcytosis vesicle identity and regulatory machinery undefined","Relative proteoform abundances in human disease tissues not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,2,9,10,14,18,36]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,2,12,27]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,9,12,13,22,28,32]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,10,12,13,22,29,34,37]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[12,27,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[17,18,23,36,37]}],"complexes":[],"partners":["CXCR1","CXCR2","TNFAIP6","SDC4","MMP9"],"other_free_text":[]},"mechanistic_narrative":"CXCL8 (interleukin-8) is a prototypical ELR+ CXC chemokine that functions as the principal neutrophil chemoattractant and activator while simultaneously acting as a potent pro-angiogenic factor and autocrine tumor growth signal. Secreted by monocytes, macrophages, epithelial cells, and tumor cells in response to IL-1, TNF, LPS, thrombin, and oncogenic Ras—through NF-κB-dependent transcription regulated by upstream IL-1R/IRAK1, PAR1/PKCα/c-Src/IKK, DCLK1/RhoA/YAP–p65, and Notch1 pathways—CXCL8 signals through two GPCRs: the IL-8-selective CXCR1 and the promiscuous CXCR2, coupling to Gαi/Ca²⁺, PI3K/AKT, ERK, p38 MAPK, and β-arrestin to drive neutrophil chemotaxis, degranulation, respiratory burst, and endothelial cell survival, proliferation, and tube formation [PMID:3480540, PMID:1840701, PMID:8702798, PMID:1281554, PMID:12496258]. Its bioactivity is fine-tuned post-translationally: N-terminal truncation by MMP-9 generates the 10–27-fold more potent CXCL8(7-77), whereas citrullination at Arg5 by peptidylarginine deiminase reduces GAG binding, CXCR2 signaling, and in vivo neutrophil recruitment [PMID:11023497, PMID:18710930, PMID:30486423]. CXCL8 is transcytosed across venular endothelium via its GAG-binding C-terminus for luminal presentation to leukocytes, a process antagonized by TSG-6 binding [PMID:9363947, PMID:24501198]. In cancer, CXCL8 sustains glioblastoma stem cell mesenchymal identity through PI3K/AKT and NF-κB, polarizes tumor-associated macrophages via CXCR2–JAK2/STAT3, and drives myelofibrosis through CXCR2-dependent hematopoietic stem cell expansion and bone marrow fibrosis [PMID:37439870, PMID:36800567]."},"prefetch_data":{"uniprot":{"accession":"P10145","full_name":"Interleukin-8","aliases":["C-X-C motif chemokine 8","Chemokine (C-X-C motif) ligand 8","Emoctakin","Granulocyte chemotactic protein 1","GCP-1","Monocyte-derived neutrophil chemotactic factor","MDNCF","Monocyte-derived neutrophil-activating peptide","MONAP","Neutrophil-activating protein 1","NAP-1","Protein 3-10C","T-cell chemotactic factor"],"length_aa":99,"mass_kda":11.1,"function":"Chemotactic factor that mediates inflammatory response by attracting neutrophils, basophils, and T-cells to clear pathogens and protect the host from infection (PubMed:18692776, PubMed:7636208). Also plays an important role in neutrophil activation (PubMed:2145175, PubMed:9623510). Released in response to an inflammatory stimulus, exerts its effect by binding to the G-protein-coupled receptors CXCR1 and CXCR2, primarily found in neutrophils, monocytes and endothelial cells (PubMed:1840701, PubMed:1891716). G-protein heterotrimer (alpha, beta, gamma subunits) constitutively binds to CXCR1/CXCR2 receptor and activation by IL8 leads to beta and gamma subunits release from Galpha (GNAI2 in neutrophils) and activation of several downstream signaling pathways including PI3K and MAPK pathways (PubMed:11971003, PubMed:8662698)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P10145/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL8","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL8","total_profiled":1310},"omim":[{"mim_id":"620956","title":"ZINC FINGER C3H1 DOMAIN-CONTAINING PROTEIN; ZFC3H1","url":"https://www.omim.org/entry/620956"},{"mim_id":"616560","title":"CD300H ANTIGEN; CD300H","url":"https://www.omim.org/entry/616560"},{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"611387","title":"CXC CHEMOKINE LIGAND 17; CXCL17","url":"https://www.omim.org/entry/611387"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":2989.3}],"url":"https://www.proteinatlas.org/search/CXCL8"},"hgnc":{"alias_symbol":["SCYB8","LUCT","LECT","MDNCF","TSG-1","IL-8","NAP-1","3-10C","MONAP","AMCF-I","LYNAP","NAF","b-ENAP","GCP-1","K60","GCP1","NAP1"],"prev_symbol":["IL8"]},"alphafold":{"accession":"P10145","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10145","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10145-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10145-F1-predicted_aligned_error_v6.png","plddt_mean":88.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL8","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL8"},"sequence":{"accession":"P10145","fasta_url":"https://rest.uniprot.org/uniprotkb/P10145.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10145/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10145"}},"corpus_meta":[{"pmid":"28529637","id":"PMC_28529637","title":"Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28529637","citation_count":611,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27578214","id":"PMC_27578214","title":"The CXCL8-CXCR1/2 pathways in cancer.","date":"2016","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27578214","citation_count":521,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24678812","id":"PMC_24678812","title":"The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.","date":"2014","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24678812","citation_count":507,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36725964","id":"PMC_36725964","title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.","date":"2023","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36725964","citation_count":402,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19904283","id":"PMC_19904283","title":"Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.","date":"2009","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19904283","citation_count":368,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12618418","id":"PMC_12618418","title":"Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases.","date":"2003","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12618418","citation_count":355,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30661053","id":"PMC_30661053","title":"Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer.","date":"2019","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/30661053","citation_count":305,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19035451","id":"PMC_19035451","title":"CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19035451","citation_count":246,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15545974","id":"PMC_15545974","title":"Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15545974","citation_count":195,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17197447","id":"PMC_17197447","title":"Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17197447","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2647892","id":"PMC_2647892","title":"Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils.","date":"1989","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2647892","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14530367","id":"PMC_14530367","title":"IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14530367","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24501198","id":"PMC_24501198","title":"TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24501198","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18710930","id":"PMC_18710930","title":"Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18710930","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35319989","id":"PMC_35319989","title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35319989","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1967588","id":"PMC_1967588","title":"Monocyte-derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily.","date":"1990","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1967588","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24276377","id":"PMC_24276377","title":"Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer.","date":"2013","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/24276377","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15342208","id":"PMC_15342208","title":"Increased CXCL8 (IL-8) expression in Multiple Sclerosis.","date":"2004","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/15342208","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35011369","id":"PMC_35011369","title":"Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35011369","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35372515","id":"PMC_35372515","title":"CXCL8 in Tumor Biology and Its Implications for Clinical Translation.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/35372515","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15974585","id":"PMC_15974585","title":"2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15974585","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27444565","id":"PMC_27444565","title":"MicroRNA-146a in Human and Experimental Ischemic AKI: CXCL8-Dependent Mechanism of Action.","date":"2016","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/27444565","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24224100","id":"PMC_24224100","title":"The Chemokine CXCL8 in Carcinogenesis and Drug Response.","date":"2013","source":"ISRN oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24224100","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32983174","id":"PMC_32983174","title":"Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32983174","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33706134","id":"PMC_33706134","title":"CXCL8 chemokine in ulcerative colitis.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33706134","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30135299","id":"PMC_30135299","title":"IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30135299","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27018308","id":"PMC_27018308","title":"Tumor-associated macrophage-derived CXCL8 could induce ERα suppression via HOXB13 in endometrial cancer.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27018308","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31827643","id":"PMC_31827643","title":"The Crucial Role of CXCL8 and Its Receptors in Colorectal Liver Metastasis.","date":"2019","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/31827643","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31105691","id":"PMC_31105691","title":"Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31105691","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25445541","id":"PMC_25445541","title":"Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25445541","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23403077","id":"PMC_23403077","title":"Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23403077","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21530579","id":"PMC_21530579","title":"CXCL8 of Scophthalmus maximus: expression, biological activity and immunoregulatory effect.","date":"2011","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21530579","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36800567","id":"PMC_36800567","title":"CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36800567","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36648332","id":"PMC_36648332","title":"Spatially resolved transcriptomics reveals pro-inflammatory fibroblast involved in lymphocyte recruitment through CXCL8 and CXCL10.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36648332","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16920985","id":"PMC_16920985","title":"c-Src mediates thrombin-induced NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16920985","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33677254","id":"PMC_33677254","title":"Tumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: Suppression by Danirixin.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33677254","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18282785","id":"PMC_18282785","title":"Roles of CXCL8 in squamous cell carcinoma proliferation and migration.","date":"2008","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18282785","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34426905","id":"PMC_34426905","title":"An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34426905","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27650493","id":"PMC_27650493","title":"CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27650493","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31805999","id":"PMC_31805999","title":"PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31805999","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37439870","id":"PMC_37439870","title":"Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages.","date":"2023","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/37439870","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21673103","id":"PMC_21673103","title":"Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21673103","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16556047","id":"PMC_16556047","title":"Mitogenic effects of interleukin-8/CXCL8 on cancer cells.","date":"2005","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16556047","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29679563","id":"PMC_29679563","title":"ShRNA-mediated knock-down of CXCL8 inhibits tumor growth in colorectal liver metastasis.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29679563","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29367006","id":"PMC_29367006","title":"Molecular characterization and functional activity of CXCL8_L3 in large yellow croaker Larimichthys crocea.","date":"2018","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29367006","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37665572","id":"PMC_37665572","title":"CXCL8 induces M2 macrophage polarization and inhibits CD8+ T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37665572","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30738331","id":"PMC_30738331","title":"Disrupting Inflammation-Associated CXCL8-CXCR1 Signaling Inhibits Tumorigenicity Initiated by Sporadic- and Colitis-Colon Cancer Stem Cells.","date":"2019","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30738331","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30578411","id":"PMC_30578411","title":"CUL1 promotes breast cancer metastasis through regulating EZH2-induced the autocrine expression of the cytokines CXCL8 and IL11.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30578411","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25445910","id":"PMC_25445910","title":"Cxcl8-l1 and Cxcl8-l2 are required in the zebrafish defense against Salmonella Typhimurium.","date":"2014","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25445910","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21299226","id":"PMC_21299226","title":"Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols.","date":"2011","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/21299226","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31025289","id":"PMC_31025289","title":"Cancer-Associated Fibroblasts Enhance Survival and Progression of the Aggressive Pancreatic Tumor Via FGF-2 and CXCL8.","date":"2019","source":"Cancer microenvironment : official journal of the International Cancer Microenvironment Society","url":"https://pubmed.ncbi.nlm.nih.gov/31025289","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30704100","id":"PMC_30704100","title":"Human Brain Endothelial CXCR2 is Inflammation-Inducible and Mediates CXCL5- and CXCL8-Triggered Paraendothelial Barrier Breakdown.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30704100","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22815748","id":"PMC_22815748","title":"Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22815748","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28057697","id":"PMC_28057697","title":"Zonula occludens-1/NF-κB/CXCL8: a new regulatory axis for tumor angiogenesis.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28057697","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16098041","id":"PMC_16098041","title":"Endothelin-1 induces CXCL1 and CXCL8 secretion in human melanoma cells.","date":"2005","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/16098041","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32272490","id":"PMC_32272490","title":"Truncation of CXCL8 to CXCL8(9-77) enhances actin polymerization and in vivo migration of neutrophils.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32272490","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28176455","id":"PMC_28176455","title":"Adiponectin promotes human jaw bone marrow mesenchymal stem cell chemotaxis via CXCL1 and CXCL8.","date":"2017","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28176455","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27008259","id":"PMC_27008259","title":"Lactobacillus rhamnosus could inhibit Porphyromonas gingivalis derived CXCL8 attenuation.","date":"2016","source":"Journal of applied oral science : revista FOB","url":"https://pubmed.ncbi.nlm.nih.gov/27008259","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24277695","id":"PMC_24277695","title":"T lymphocyte-dependent and -independent regulation of Cxcl8 expression in zebrafish intestines.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24277695","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23894602","id":"PMC_23894602","title":"MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23894602","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22064657","id":"PMC_22064657","title":"Regulation of CXCL8/IL-8 expression by zonula occludens-1 in human breast cancer cells.","date":"2011","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22064657","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22030312","id":"PMC_22030312","title":"Bronchial epithelial cells release IL-6, CXCL1 and CXCL8 upon mast cell interaction.","date":"2011","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22030312","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33221386","id":"PMC_33221386","title":"CXCL5, CXCL8, and CXCL10 regulation by bacteria and mechanical forces in periodontium.","date":"2020","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/33221386","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34038586","id":"PMC_34038586","title":"H. pylori infection induces CXCL8 expression and promotes gastric cancer progress through downregulating KLF4.","date":"2021","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34038586","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31235521","id":"PMC_31235521","title":"Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31235521","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36504808","id":"PMC_36504808","title":"CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36504808","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25646691","id":"PMC_25646691","title":"Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25646691","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34981477","id":"PMC_34981477","title":"The Role of Chemokines in Cardiovascular Diseases and the Therapeutic Effect of Curcumin on CXCL8 and CCL2 as Pathological Chemokines in Atherosclerosis.","date":"2021","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/34981477","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29207576","id":"PMC_29207576","title":"Glycosaminoglycan-Mediated Downstream Signaling of CXCL8 Binding to Endothelial Cells.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29207576","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21645500","id":"PMC_21645500","title":"LecT-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21645500","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31681401","id":"PMC_31681401","title":"Consensus-Expressed CXCL8 and MMP9 Identified by Meta-Analyzed Perineural Invasion Gene Signature in Gastric Cancer Microarray Data.","date":"2019","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31681401","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24629040","id":"PMC_24629040","title":"Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24629040","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29802127","id":"PMC_29802127","title":"Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29802127","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31938199","id":"PMC_31938199","title":"Complementary action of CXCL1 and CXCL8 in pathogenesis of gastric carcinoma.","date":"2018","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31938199","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34680333","id":"PMC_34680333","title":"Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34680333","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34284965","id":"PMC_34284965","title":"CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.","date":"2021","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34284965","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32038715","id":"PMC_32038715","title":"Transcriptional Profiling Reveals the Regulatory Role of CXCL8 in Promoting Colorectal Cancer.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32038715","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2200751","id":"PMC_2200751","title":"Coding region structure of interleukin-8 gene of human lung giant cell carcinoma LU65C cells that produce LUCT/interleukin-8: homogeneity in interleukin-8 genes.","date":"1990","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/2200751","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26086093","id":"PMC_26086093","title":"27-Oxygenated cholesterol induces expression of CXCL8 in macrophages via NF-κB and CD88.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26086093","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27351369","id":"PMC_27351369","title":"Thromboxane A2 Regulates CXCL1 and CXCL8 Chemokine Expression in the Nasal Mucosa-Derived Fibroblasts of Chronic Rhinosinusitis Patients.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27351369","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30486423","id":"PMC_30486423","title":"Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30486423","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28736254","id":"PMC_28736254","title":"Bisphenol A affects trophoblast invasion by inhibiting CXCL8 expression in decidual stromal cells.","date":"2017","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28736254","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36078096","id":"PMC_36078096","title":"The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36078096","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38793070","id":"PMC_38793070","title":"IL-8 (CXCL8) Correlations with Psychoneuroimmunological Processes and Neuropsychiatric Conditions.","date":"2024","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38793070","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35321317","id":"PMC_35321317","title":"EBV-Induced CXCL8 Upregulation Promotes Vasculogenic Mimicry in Gastric Carcinoma via NF-κB Signaling.","date":"2022","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35321317","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26535082","id":"PMC_26535082","title":"Peptidoglycan Up-Regulates CXCL8 Expression via Multiple Pathways in Monocytes/Macrophages.","date":"2015","source":"Biomolecules & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26535082","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22763041","id":"PMC_22763041","title":"Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22763041","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26870616","id":"PMC_26870616","title":"Role of heparan sulfate in mediating CXCL8-induced endothelial cell migration.","date":"2016","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/26870616","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26231926","id":"PMC_26231926","title":"Assessment of CCL2 and CXCL8 chemokines in serum, bronchoalveolar lavage fluid and lung tissue samples from dogs affected with canine idiopathic pulmonary fibrosis.","date":"2015","source":"Veterinary journal (London, England : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/26231926","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36369000","id":"PMC_36369000","title":"Thrombin induces IL-8/CXCL8 expression by DCLK1-dependent RhoA and YAP activation in human lung epithelial cells.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/36369000","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21669195","id":"PMC_21669195","title":"Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases.","date":"2011","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21669195","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18389476","id":"PMC_18389476","title":"Human Thy-1 induces secretion of matrix metalloproteinase-9 and CXCL8 from human neutrophils.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18389476","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39755693","id":"PMC_39755693","title":"CXCL8 modulates M0 macrophage proliferation and polarization to influence tumor progression in cervical cancer.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39755693","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31986121","id":"PMC_31986121","title":"Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31986121","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30521103","id":"PMC_30521103","title":"Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33.","date":"2018","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30521103","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35898871","id":"PMC_35898871","title":"FOXS1 Promotes Tumor Progression by Upregulating CXCL8 in Colorectal Cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35898871","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37168340","id":"PMC_37168340","title":"Guanylate binding protein 5 accelerates gastric cancer progression via the JAK1-STAT1/GBP5/CXCL8 positive feedback loop.","date":"2023","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37168340","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28039493","id":"PMC_28039493","title":"New Markers in Atherosclerosis: Thrombospondin-2 (THBS-2) and Leukocyte Cell-Derived Chemotaxin-2 (LECT-2); An Immunohistochemical Study.","date":"2016","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/28039493","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34072622","id":"PMC_34072622","title":"The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery-The GL-Lect Hypothesis.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34072622","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38636892","id":"PMC_38636892","title":"NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38636892","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1281554","id":"PMC_1281554","title":"Interleukin-8 as a macrophage-derived mediator of angiogenesis.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1281554","citation_count":1853,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1699135","id":"PMC_1699135","title":"Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1699135","citation_count":1317,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2648569","id":"PMC_2648569","title":"The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes.","date":"1989","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2648569","citation_count":1109,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12626597","id":"PMC_12626597","title":"IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12626597","citation_count":1072,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3260265","id":"PMC_3260265","title":"Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.","date":"1988","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/3260265","citation_count":1053,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1840701","id":"PMC_1840701","title":"Structure and functional expression of a human interleukin-8 receptor.","date":"1991","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1840701","citation_count":1016,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3480540","id":"PMC_3480540","title":"Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3480540","citation_count":987,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12952969","id":"PMC_12952969","title":"Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12952969","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1639201","id":"PMC_1639201","title":"Interleukin-8, a chemotactic and inflammatory cytokine.","date":"1992","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/1639201","citation_count":814,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15542429","id":"PMC_15542429","title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.","date":"2004","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15542429","citation_count":674,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12782716","id":"PMC_12782716","title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12782716","citation_count":588,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9363947","id":"PMC_9363947","title":"Transcytosis and surface presentation of IL-8 by venular endothelial cells.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9363947","citation_count":566,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11023497","id":"PMC_11023497","title":"Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11023497","citation_count":546,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19805069","id":"PMC_19805069","title":"Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19805069","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21300928","id":"PMC_21300928","title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","date":"2011","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21300928","citation_count":510,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22869038","id":"PMC_22869038","title":"Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia.","date":"2012","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22869038","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3322281","id":"PMC_3322281","title":"Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes.","date":"1987","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3322281","citation_count":468,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2663993","id":"PMC_2663993","title":"Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8.","date":"1989","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2663993","citation_count":453,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2184886","id":"PMC_2184886","title":"Three-dimensional structure of interleukin 8 in solution.","date":"1990","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2184886","citation_count":446,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18678243","id":"PMC_18678243","title":"Peripheral cytokines profile in Parkinson's disease.","date":"2008","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18678243","citation_count":425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20148189","id":"PMC_20148189","title":"MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8.","date":"2009","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/20148189","citation_count":415,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11083887","id":"PMC_11083887","title":"Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.","date":"2000","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/11083887","citation_count":414,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9323208","id":"PMC_9323208","title":"Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9323208","citation_count":396,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12496258","id":"PMC_12496258","title":"Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12496258","citation_count":387,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28595336","id":"PMC_28595336","title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.","date":"2017","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28595336","citation_count":374,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8702798","id":"PMC_8702798","title":"The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702798","citation_count":354,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53565,"output_tokens":7742,"usd":0.138412},"stage2":{"model":"claude-opus-4-6","input_tokens":11631,"output_tokens":5132,"usd":0.279683},"total_usd":0.894134,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":68329,"output_tokens":10426,"usd":0.180689},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14815,"output_tokens":4913,"usd":0.29535}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"CXCL8 (MDNCF) binds two distinct receptor polypeptides of ~67 kDa and ~59 kDa on human neutrophils with approximately 20,000 receptors per cell and a high-affinity Kd of ~8×10⁻¹⁰ M; these receptors are distinct from receptors for IL-1α, TNF-α, FMLP, C5a, leukotriene B4, and PAF.\",\n      \"method\": \"125I-labeled recombinant CXCL8 radioligand binding, Scatchard analysis, SDS-PAGE of chemically crosslinked receptor-ligand complex\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay with Scatchard analysis and crosslinking, foundational receptor identification paper\",\n      \"pmids\": [\"2647892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The CXCL8 (IL-8) gene is located at chromosome 4q12-q21, resides in a gene cluster with other platelet factor 4 superfamily members (PF4, MGSA, IFN-γ-induced factor), and its coding region comprises 4 exons and 3 introns; all human cells appear to possess a homogeneous IL-8 coding region.\",\n      \"method\": \"Human-rodent somatic cell hybrid panel mapping, in situ hybridization, PCR amplification of genomic DNA from multiple cell types\",\n      \"journal\": \"Human genetics / Immunology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct chromosomal mapping combined with genomic structure analysis; replicated across two papers (PMID:1967588, PMID:2200751)\",\n      \"pmids\": [\"1967588\", \"2200751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mouse CXCR1 is a functional receptor for human CXCL8 (and GCP-2/CXCL6), demonstrated by binding, GTPγS exchange stimulation, and chemotaxis of mCXCR1-transfected cells; unlike human CXCR2, mCXCR1 does not respond to ENA-78/CXCL5, NAP-2/CXCL7, or GROα/β/γ.\",\n      \"method\": \"Receptor binding assay, GTPγS exchange assay, chemotaxis of transfected cells, RT-PCR tissue distribution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal functional assays (binding, GTPγS, chemotaxis) in a single study\",\n      \"pmids\": [\"17197447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-8/CXCL8 and GROα/CXCL1 induce chondrocyte hypertrophic differentiation (type X collagen, MMP-13 expression, alkaline phosphatase activity, matrix calcification) via p38 MAPK signaling and transglutaminase 2 (TG2) activity; TG2 knockout chondrocytes fail to upregulate hypertrophy markers in response to KC (murine GROα homologue).\",\n      \"method\": \"Primary human/bovine chondrocyte cultures, CXCR2 ligand specificity testing, p38 MAPK inhibitor experiments, mouse knee chondrocytes from TG2-knockout animals\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout validation combined with pharmacological inhibition and multiple cellular readouts\",\n      \"pmids\": [\"14530367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-8/CXCL8 acts as an autocrine growth factor for NSCLC cells; its mitogenic function is mediated primarily through CXCR1 (not CXCR2), as demonstrated by receptor-specific neutralizing antibody blocking of cell proliferation.\",\n      \"method\": \"Anti-IL-8 neutralizing antibody, anti-CXCR1 and anti-CXCR2 antibody blocking assays, PCNA expression, cell cycle analysis, RT-PCR, flow cytometry\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific antibody blockade with multiple proliferation readouts, single lab\",\n      \"pmids\": [\"15545974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ketoprofen and its derivative repertaxin are noncompetitive inhibitors of CXCL8-induced neutrophil chemotaxis that bind within the transmembrane region of CXCR1; binding site confirmed by alanine scanning mutagenesis and photoaffinity labeling.\",\n      \"method\": \"Molecular modeling, alanine scanning mutagenesis of CXCR1, photoaffinity labeling, neutrophil chemotaxis assay\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis and photoaffinity labeling confirm binding site; multiple orthogonal methods\",\n      \"pmids\": [\"15974585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Thrombin stimulates IL-8/CXCL8 expression in human lung epithelial cells via PAR1 and PAR4, activating the phosphoinositide-PLC/PKCα/c-Src/IKKαβ/NF-κB signaling cascade; thrombin induces complex formation between PKCα, c-Src, and IKKαβ, and NF-κB p65 binding to the κB site of the CXCL8 promoter drives expression.\",\n      \"method\": \"Dominant-negative c-Src mutant, pharmacological inhibitors, NF-κB luciferase reporter with κB site mutation, co-immunoprecipitation of PKCα/c-Src/IKKαβ complex, kinase activity assays, nuclear translocation assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution-level pathway delineation with dominant-negative constructs, promoter mutants, and co-IP; multiple orthogonal methods\",\n      \"pmids\": [\"16920985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PAD (peptidylarginine deiminase) citrullinates CXCL8 at arginine-5, generating CXCL8(1-77)Cit5; this modification reduces affinity for glycosaminoglycans, decreases CXCR2-dependent calcium signaling and ERK1/2 phosphorylation, confers resistance to thrombin/plasmin-mediated proteolytic potentiation, and abolishes neutrophil extravasation in vivo despite retained in vitro chemotactic activity.\",\n      \"method\": \"Identification of natural citrullinated CXCL8 from leukocytes, in vitro PAD citrullination, GAG binding assays, calcium flux assay, ERK phosphorylation assay, in vivo peritoneal neutrophil extravasation, cornea angiogenesis assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — identification of natural PTM combined with reconstituted in vitro and in vivo functional assays; multiple orthogonal readouts\",\n      \"pmids\": [\"18710930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL8 secreted by pancreatic cancer cells enhances HUVEC proliferation, invasion, and tube formation (angiogenesis), while CXCL12 from fibroblasts enhances CXCL8 production in tumor cells and promotes tumor cell invasion; the two chemokines cooperatively drive angiogenesis through CXCR2 and CXCR4 paracrine mechanisms.\",\n      \"method\": \"ELISA, RT-PCR, MTS proliferation assay, Matrigel invasion assay, HUVEC tube formation assay, co-culture experiments\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro functional assays in co-culture system, single lab\",\n      \"pmids\": [\"19035451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL8 binding to endothelial heparan sulfate mediates endothelial cell migration; removal of heparan sulfate by heparinase III suppresses CXCL8-induced activation of Rho GTPases (Cdc42, Rac1, RhoA), actin polymerization and stress fiber formation, and abrogates wound healing migration.\",\n      \"method\": \"Heparinase III enzymatic HS removal, wound healing assay, Rho GTPase activity assay, actin cytoskeleton imaging\",\n      \"journal\": \"PeerJ\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic perturbation with multiple cellular readouts; single lab\",\n      \"pmids\": [\"26870616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL8 is released from neutrophils upon interaction with human Thy-1 (CD90) on activated dermal endothelial cells/fibroblasts; blocking CD18 (Mac-1) on neutrophils or Thy-1 on endothelial cells suppresses this CXCL8 secretion, establishing a Thy-1/CD18 adhesion-dependent mechanism of autocrine neutrophil recruitment.\",\n      \"method\": \"Recombinant Thy-1 binding, blocking antibodies against Thy-1 and CD18, ELISA measurement of CXCL8 release, collagen-IV/Matrigel migration assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking validated with recombinant protein and antibodies; single lab\",\n      \"pmids\": [\"18389476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Met receptor tyrosine kinase signaling in pancreatic cancer cells regulates secretion of pro-angiogenic CXCL8; Met knockdown reduces CXCL8 secretion, tumor angiogenesis, and tumor burden in vivo. As CXCR1/2 are absent from tumor cells, this operates via a paracrine mechanism on the tumor microenvironment.\",\n      \"method\": \"RNAi knockdown of Met, ELISA for CXCL8, orthotopic tumor model in mice, cell invasion/migration assay, CXCR1/CXCR2 expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro validation with RNAi and receptor expression analysis; single lab\",\n      \"pmids\": [\"22815748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TSG-6 directly binds CXCL8 at its glycosaminoglycan-binding site (KD ~25 nM), blocking CXCL8 association with heparin and cell-surface glycosaminoglycans, impairing CXCL8 transcytosis across endothelium, and suppressing CXCL8-mediated neutrophil chemotaxis; this identifies TSG-6 as the first soluble mammalian chemokine-binding protein.\",\n      \"method\": \"Direct binding assay (KD measured), heparin competition assay, transendothelial migration assay, in vivo neutrophil recruitment, site-directed binding to GAG-binding domain\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative binding assay combined with functional in vitro and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"24501198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL8 promoter activity and expression are regulated by ZO-1 (zonula occludens-1) when ZO-1 delocalizes from tight junctions; ZO-1 siRNA downregulates CXCL8, and ZO-1 overexpression in non-invasive cells upregulates CXCL8 via promoter activation independent of β-catenin.\",\n      \"method\": \"siRNA knockdown, cDNA overexpression, GeneArray analysis, luciferase reporter assay of CXCL8 promoter\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter plus bidirectional ZO-1 manipulation; single lab\",\n      \"pmids\": [\"22064657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZO-1 drives CXCL8 expression via the NF-κB pathway; cytonuclear ZO-1 activates IκBα and p65 phosphorylation, p65 silencing abolishes CXCL8 induction, and a 173-bp region of the CXCL8 promoter containing an NF-κB site mediates this response; this ZO-1/NF-κB/CXCL8 axis promotes tumor angiogenesis.\",\n      \"method\": \"siRNA and cDNA transfections, mutated CXCL8 promoter-luciferase constructs, NF-κB pathway activation analysis (IκBα/p65 phosphorylation), ex vivo and in vivo angiogenesis assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter mutagenesis confirms NF-κB site; pathway validation with genetic and biochemical approaches; functional angiogenesis assays\",\n      \"pmids\": [\"28057697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Evasin-3, a tick salivary protein, directly binds CXCL8 and disrupts its glycosaminoglycan-binding site and its interaction with CXCR2, thereby inhibiting CXCL8-induced neutrophil migration; structure determined by solution NMR, and synthetic Evasin-3 variants (KD 13–27 nM by SPR) retain neutrophil migration inhibitory activity.\",\n      \"method\": \"Solution NMR structure determination of Evasin-3 and CXCL8-Evasin-3 complex, surface plasmon resonance binding (KD measurement), neutrophil chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure plus quantitative binding and functional validation\",\n      \"pmids\": [\"31235521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Citrullination of CXCL8 at position 5 and NH2-terminal truncation to CXCL8(6-77) each moderately enhance CXCR1 and CXCR2 internalization, increase Gαi-dependent signaling, and promote β-arrestin recruitment; CXCL8(6-77) specifically enhances β-arrestin 2 recruitment to both receptors, while [Cit5]CXCL8(1-77) only enhances β-arrestin 2 recruitment to CXCR2; neither modification biases signaling between Gαi and β-arrestin pathways.\",\n      \"method\": \"Chemically synthesized CXCL8 variants, receptor internalization assays on human neutrophils, β-arrestin recruitment assays, Gαi signaling assay\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemically defined synthetic variants tested in multiple signaling assays; mechanistic dissection of PTM effects on receptor bias\",\n      \"pmids\": [\"30486423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NH2-terminal truncation of CXCL8 to CXCL8(9-77) strongly potentiates actin polymerization in human neutrophils and significantly enhances in vivo neutrophil recruitment to the peritoneal cavity compared to CXCL8(6-77), while effects on CD62L shedding, adhesion molecule expression, degranulation, and phagocytosis are unchanged.\",\n      \"method\": \"Comparison of natural CXCL8 isoforms: actin polymerization assay, calcium signaling, CD62L/CD11a/CD11b/CD15 expression, degranulation assay, phagocytosis, in vitro chemotaxis, in vivo murine peritoneal recruitment\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo studies with multiple orthogonal functional readouts comparing defined natural isoforms\",\n      \"pmids\": [\"32272490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Glycosaminoglycan (GAG) binding of CXCL8 to endothelial cells triggers downstream signaling independent of CXCR1/CXCR2; syndecan-4 (SDC4) is identified as a potential proteoglycan co-receptor; GAG removal by heparinase III or chondroitinase ABC alters CXCL8-induced endothelial protein expression, including changes in cytoskeletal regulators zyxin and caldesmon.\",\n      \"method\": \"Gene array, RT-PCR, flow cytometry for SDC4, enzymatic GAG depolymerization with heparinase III and chondroitinase ABC, proteomic analysis of CXCL8-treated endothelial cells\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — enzymatic perturbation and proteomics without direct receptor validation; single lab\",\n      \"pmids\": [\"29207576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Thrombin induces IL-8/CXCL8 expression in human lung epithelial cells via DCLK1 activation of RhoA, leading to YAP dephosphorylation at Ser127, nuclear translocation of YAP, YAP/p65 complex formation at the NF-κB site of the CXCL8 promoter; this cascade is upstream-activated by ERK signaling.\",\n      \"method\": \"siRNA knockdown of DCLK1/RhoA/YAP, pharmacological inhibitors (DCLK1 inhibitor, ERK inhibitor), κB-luciferase reporter assay, ChIP assay for YAP and p65 at CXCL8 promoter, Western blot for phosphorylation states, immunofluorescence for YAP localization\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP assay directly demonstrates YAP/p65 binding to CXCL8 promoter; multiple genetic and biochemical approaches\",\n      \"pmids\": [\"36369000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL8/CXCR2 signaling mediates bone marrow fibrosis in myelofibrosis; CXCL8 enhances MPN hematopoietic stem/progenitor cell proliferation in vitro; genetic deletion of Cxcr2 in a murine MPLW515L model abrogates fibrosis and extends survival; pharmacologic CXCR1/2 inhibition attenuates fibrosis and synergizes with JAK inhibitor therapy.\",\n      \"method\": \"Single-cell transcriptomics, cytokine secretion assays, in vitro proliferation assay with exogenous CXCL8, genetic Cxcr2 deletion in adoptive transfer mouse model, pharmacologic CXCR1/2 inhibition in vivo\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic knockout in vivo model with survival endpoint plus in vitro proliferation; multiple orthogonal methods\",\n      \"pmids\": [\"36800567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL8 secreted by mesenchymal glioblastoma stem cells activates PI3K/AKT and NF-κB signaling in an autocrine (cell-intrinsic) manner to maintain GSC proliferation and self-renewal; CXCL8 additionally drives M2-like TAM polarization via a paracrine CXCR2-JAK2/STAT3 axis; dual inhibition of both cascades suppresses tumor growth and prolongs survival in orthotopic xenograft mice.\",\n      \"method\": \"Patient-derived GSCs, xenograft murine model, RNA sequencing, epigenetic profiling, genetic and pharmacologic inhibition of CXCL8, PI3K/AKT, NF-κB, CXCR2, JAK2/STAT3\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo xenograft validation combined with mechanistic pathway dissection using multiple genetic/pharmacologic approaches\",\n      \"pmids\": [\"37439870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL8 from tumor-associated macrophages (TAMs) induces PD-L1 expression on macrophages in gastric cancer, suppressing CD8+ T cell function; CSF-2 facilitates macrophage-derived CXCL8 secretion; CXCR2 inhibitor reparixin reduces PD-L1+ macrophages and promotes antitumor immunity.\",\n      \"method\": \"Flow cytometry of fresh tumor tissue, in vitro culture with CXCR2 inhibitor (reparixin), RT-PCR, immunohistochemistry in 420 patients\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pharmacologic CXCR2 blockade with cellular phenotyping; mechanistic link to PD-L1 supported but primarily observational in patient tissue\",\n      \"pmids\": [\"30661053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KLF4 transcriptionally suppresses CXCL8 by binding the CXCL8 promoter; H. pylori CagA induces CXCL8 expression while downregulating KLF4, and CXCL8 stimulation in turn reduces KLF4 protein expression, creating a positive feedback loop that promotes gastric cancer proliferation and migration.\",\n      \"method\": \"ChIP assay (KLF4 binding to CXCL8 promoter), KLF4 knockdown/overexpression, H. pylori infection and CagA transduction, in vivo tumor growth assay\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP directly demonstrates KLF4 promoter occupancy at CXCL8; bidirectional genetic manipulation with in vivo validation\",\n      \"pmids\": [\"34038586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Gemcitabine enhances CXCL8 expression in human pancreatic cancer cells through reactive oxygen species (ROS) generation and NF-κB activation; CXCL8 does not affect gemcitabine-mediated inhibition of cancer cell proliferation in vitro but promotes tumor neovascularization in vivo, counteracting gemcitabine's anti-tumor effects.\",\n      \"method\": \"ROS assay, NF-κB activation assay, anti-CXCL8 antibody in vivo treatment, xenograft tumor model, intra-tumoral vascularity measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization antibody experiment with mechanistic ROS/NF-κB pathway identification; single lab\",\n      \"pmids\": [\"25646691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In triple-negative breast cancer, Notch1 activation (downstream of TNFα-induced NF-κB/p65 in tumor:stroma contact co-cultures) drives CXCL8 production primarily in tumor cells; Notch1 siRNA reduces contact-dependent CXCL8 elevation, and CXCL8 or p65 knockdown confirms the NF-κB→Notch1→CXCL8 cascade mediating pro-metastatic activities.\",\n      \"method\": \"siRNA knockdown of Notch1, CXCL8, p65; CRISPR/Cas9 CXCL8 knockout; γ-secretase inhibitor DAPT; TNBC:MSC contact co-cultures; migration/invasion assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic tools (siRNA, CRISPR) with pharmacologic validation; single lab\",\n      \"pmids\": [\"31105691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Radiotherapy induces CXCL8 secretion from tumor cells with senescence features via NF-κB and mTOR signaling, which causes directional migration of CD56dim NK cells to irradiated tumors, linking senescence-associated CXCL8 release to innate immune surveillance.\",\n      \"method\": \"Randomized controlled pancreatic cancer trial (translational), experimental models with NF-κB and mTOR inhibitors, NK cell migration assay, adoptive NK cell transfer in xenografted mice\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (NF-κB/mTOR→CXCL8→NK migration) validated in experimental models with in vivo confirmation; clinical correlation\",\n      \"pmids\": [\"35319989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL8 induces M2 macrophage polarization in colorectal cancer via STAT3 signaling activation, leading to increased PD-L1+ M2 macrophage infiltration and decreased PD-1+ CD8+ T cell recruitment, generating an immunosuppressive tumor microenvironment.\",\n      \"method\": \"In vitro and in vivo co-culture experiments, STAT3 signaling pathway analysis, immunohistochemistry, multiplexed immunohistochemistry, murine CRC model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway (CXCL8→STAT3→M2 polarization) identified with in vivo validation; single lab\",\n      \"pmids\": [\"37665572\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL8 is a secreted CXC chemokine that signals through CXCR1 and CXCR2 (G protein-coupled receptors) and the atypical receptor ACKR1, activating Gαi, β-arrestin, PI3K/AKT, NF-κB, JAK2/STAT3, p38 MAPK, and RhoA/Cdc42 downstream pathways; its activity is fine-tuned by PAD-mediated citrullination at Arg-5 and proteolytic NH2-terminal truncation (which alter GAG affinity, receptor internalization, and in vivo neutrophil recruitment potency), and by interaction with heparan sulfate proteoglycans (including syndecan-4) that facilitate haptotactic gradient formation; CXCL8 transcription is controlled by NF-κB (activated upstream by thrombin/PAR1/4 via PKCα/c-Src/IKK, ZO-1 cytonuclear relocation, Notch1, or DCLK1/RhoA/YAP), and negatively regulated by KLF4 promoter binding; the chemokine drives neutrophil recruitment, promotes angiogenesis via endothelial CXCR2, maintains glioblastoma stem cell self-renewal and TAM M2 polarization through CXCR2-JAK2/STAT3, and mediates bone marrow fibrosis in myeloproliferative neoplasms.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"CXCL8 (MDNCF/NAF/IL-8) was purified from LPS-stimulated human monocyte conditioned medium as a 7-kDa protein that acts as a potent and specific neutrophil chemoattractant, with activity comparable to fMet-Leu-Phe, but without chemotactic activity toward monocytes.\",\n      \"method\": \"Protein purification (anion-exchange, gel filtration, HPLC), chemotaxis assay, SDS-PAGE\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification to homogeneity with functional validation; two independent labs (Yoshimura/Matsushima and Walz/Baggiolini) reported essentially identical protein\",\n      \"pmids\": [\"3480540\", \"3322281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The cDNA for CXCL8 (MDNCF) was cloned from LPS-stimulated human monocytes, encoding a 99-aa precursor with a signal sequence; mature protein begins at Ser-28 (72 aa). MDNCF mRNA was induced >10-fold within 1 h by LPS, IL-1, or TNF, but not by IFN-γ, IFN-α, or IL-2.\",\n      \"method\": \"cDNA cloning, Northern blot, mRNA induction assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with functional mRNA induction mapping; foundational paper\",\n      \"pmids\": [\"3260265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CXCL8 (NAP-1) is chemotactic not only for neutrophils but also for T lymphocytes; intradermal injection caused dose-dependent accumulation of both neutrophils and lymphocytes in rats.\",\n      \"method\": \"In vitro chemotaxis assay, in vivo rat injection model\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro and in vivo functional demonstration with purified/recombinant protein\",\n      \"pmids\": [\"2648569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Two distinct CXCL8-binding polypeptides were identified on human neutrophils (~67 kDa and ~59 kDa) by chemical cross-linking; Scatchard analysis revealed ~20,000 high-affinity receptors per cell (Kd ~8×10⁻¹⁰ M). These receptors are distinct from IL-1α, TNF-α, fMLP, C5a, LTB4, and PAF receptors.\",\n      \"method\": \"¹²⁵I-ligand binding, Scatchard analysis, chemical cross-linking, SDS-PAGE\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding and cross-linking identifying receptor polypeptides with Kd determination\",\n      \"pmids\": [\"2647892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The CXCL8 gene (MDNCF/IL-8) consists of 4 exons and 3 introns. The 5'-flanking region contains potential binding sites for AP-1, AP-2, IRF-1, HNF-1, glucocorticoid response element, and heat shock element, providing a molecular basis for its transcriptional regulation by inflammatory stimuli and suppression by glucocorticoids.\",\n      \"method\": \"Genomic DNA cloning and sequencing, promoter analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete genomic structure determination with regulatory element identification\",\n      \"pmids\": [\"2663993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The three-dimensional solution structure of the CXCL8 dimer was solved by NMR spectroscopy: two antiparallel α-helices (~24 Å long, separated by ~14 Å) lie on a six-stranded antiparallel β-sheet platform; the two C-terminal α-helices were proposed to form the receptor-binding site.\",\n      \"method\": \"NMR spectroscopy, hybrid distance geometry-dynamical simulated annealing (1880 distance restraints, 362 torsion angle restraints)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution NMR structure with extensive restraints and precise atomic coordinates\",\n      \"pmids\": [\"2184886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The CXCL8 gene maps to human chromosome 4q12–q21, co-localizing with platelet factor 4, MGSA, and IFN-γ-induced factor—all members of the platelet factor 4 gene superfamily—establishing CXCL8 as part of this gene cluster.\",\n      \"method\": \"Human-rodent somatic cell hybrid panel, in situ hybridization, RFLP analysis\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping using two orthogonal methods\",\n      \"pmids\": [\"1967588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The CXCL8 coding region consists of 4 exons and 3 introns and is homogeneous across human cell types; the primary translation product carries an N-terminal AVLPR sequence (LUCT form) that is subsequently truncated to generate the mature form without this extension.\",\n      \"method\": \"PCR from genomic DNA of multiple cell types, sequencing\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genomic PCR across multiple cell sources confirming coding region homogeneity and identifying N-terminal processing\",\n      \"pmids\": [\"2200751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A cDNA encoding the CXCL8 receptor (IL-8RA/CXCR1) was cloned from human neutrophils; the protein is a G protein-coupled receptor (GPCR) 29% identical to fMLP and C5a receptors. Transfected mammalian cells bound IL-8 with high affinity and responded with transient calcium mobilization, establishing CXCR1 as a functional GPCR for CXCL8.\",\n      \"method\": \"cDNA expression cloning, radioligand binding, calcium mobilization assay in transfected cells\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular cloning with functional reconstitution in heterologous cells\",\n      \"pmids\": [\"1840701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Macrophage-derived CXCL8 (IL-8) is potently angiogenic: recombinant IL-8 induced endothelial cell proliferation and chemotaxis in vitro and angiogenesis in the rat cornea in vivo. Anti-IL-8 antibodies blocked angiogenic activity of LPS-stimulated monocyte conditioned medium, and an IL-8 antisense oligonucleotide specifically blocked monocyte-induced angiogenic activity.\",\n      \"method\": \"Rat cornea implant angiogenesis assay, HUVEC proliferation and chemotaxis assay, neutralizing antibody blockade, antisense oligonucleotide\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (in vivo cornea, in vitro cell assays, antibody neutralization, antisense) demonstrating angiogenic function\",\n      \"pmids\": [\"1281554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CXCL8 activates neutrophils inducing chemotaxis, exocytosis, and the respiratory burst; it is produced by phagocytes and mesenchymal cells in response to IL-1 or TNF stimulation.\",\n      \"method\": \"Neutrophil functional assays (chemotaxis, exocytosis, oxidative burst), cell stimulation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assays in primary neutrophils, replicated across multiple groups\",\n      \"pmids\": [\"1639201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CXCL8 (IL-8) signals through two receptor subtypes with distinct selectivity: IL8RA (CXCR1) is highly selective for IL-8 (EC50 ~4 nM) with weak responses to other ELR+ CXC chemokines; IL8RB (CXCR2) is promiscuous, responding potently to GROα/β/γ, NAP-2, ENA-78, and IL-8 (EC50 1–11 nM). Receptor selectivity was determined by calcium flux in transfected HEK293 cells and competitive radioligand binding.\",\n      \"method\": \"Calcium flux assay in HEK293 cells transfected with CXCR1 or CXCR2, competitive radioligand binding with ¹²⁵I-labeled chemokines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative pharmacological characterization in defined reconstituted system with multiple ligands and binding assays\",\n      \"pmids\": [\"8702798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CXCL8 is transcytosed across venular endothelial cells from the abluminal to luminal surface, where it is presented on EC membrane projections to adherent leukocytes. The intact C-terminus of IL-8 (its glycosaminoglycan-binding/immobilization domain) is required for EC binding, transcytosis, and in vivo pro-emigratory activity.\",\n      \"method\": \"Electron microscopy of transcytosis, C-terminal deletion mutants, in vivo leukocyte emigration assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural visualization by EM plus functional mutagenesis and in vivo validation\",\n      \"pmids\": [\"9363947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Neutrophil gelatinase B (MMP-9) cleaves full-length CXCL8(1-77) to generate CXCL8(7-77), which is 10–27-fold more potent in neutrophil activation (Ca²⁺ flux, gelatinase B secretion, chemotaxis), correlating with enhanced binding to neutrophils and increased CXCR1 signaling. This represents a positive feedback loop between MMP-9 and IL-8. In contrast, MMP-9 degrades CTAP-III, PF-4, and GRO-α but leaves RANTES and MCP-2 intact.\",\n      \"method\": \"In vitro MMP-9 cleavage, neutrophil Ca²⁺ signaling, degranulation assay, chemotaxis assay, receptor binding, CXCR1/CXCR2-transfected cell lines\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution of proteolytic processing linked to receptor-specific functional potentiation via multiple orthogonal assays\",\n      \"pmids\": [\"11023497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CXCL8 (IL-8) elicits angiogenic responses (stress fiber assembly, chemotaxis, ERK1/2 phosphorylation, tube formation) in human intestinal microvascular endothelial cells (HIMEC) specifically through CXCR2 (not CXCR1, which is absent on HIMEC). ERK1/2 and PI3K inhibitors abrogated these responses.\",\n      \"method\": \"RT-PCR, immunohistochemistry, flow cytometry, Western blot, neutralizing antibody, pharmacological inhibition, proliferation/chemotaxis assays, tube formation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific attribution using neutralizing antibodies plus signaling pathway dissection with multiple inhibitors in primary cells\",\n      \"pmids\": [\"12496258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IL-8 directly promotes endothelial cell survival, proliferation, and MMP-2/MMP-9 production via CXCR1- and CXCR2-expressing endothelial cells. IL-8 inhibited apoptosis and enhanced Bcl-xL:Bcl-xS and Bcl-2:Bax ratios in HUVECs, and neutralizing anti-IL-8 antibody blocked capillary tube formation.\",\n      \"method\": \"CXCR1/CXCR2 expression analysis (RT-PCR, protein), proliferation assay, apoptosis assay, anti-apoptotic gene expression, MMP production, tube formation assay, neutralizing antibody\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with neutralization in primary endothelial cells\",\n      \"pmids\": [\"12626597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCL8 (IL-8) and GROα/CXCL1 induce chondrocyte hypertrophic differentiation (type X collagen, MMP-13, alkaline phosphatase expression, matrix calcification) via CXCR1 and CXCR2 through p38 MAPK signaling. Transglutaminase 2 (TG2) is essential for CXCL8-induced hypertrophy and calcification, acting downstream of p38.\",\n      \"method\": \"Primary human/bovine/mouse chondrocyte cultures, CXCR1/CXCR2 expression confirmation, p38 inhibition, TG2 knockout mouse chondrocytes, gene/activity assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (TG2 KO) plus pharmacological (p38 inhibitor) epistasis in primary cells with multiple differentiation markers\",\n      \"pmids\": [\"14530367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Oncogenic Ras signaling drives transcriptional upregulation of CXCL8 in tumor cells, and Ras-dependent CXCL8 secretion is required for tumor-associated inflammation and neovascularization in vivo. Ectopic CXCL8 expression rescued angiogenesis in Ras-signaling-impaired tumor xenografts.\",\n      \"method\": \"Tumor xenograft model, Ras signaling manipulation, CXCL8 reporter assays, in vivo angiogenesis assessment\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic rescue experiment identifying CXCL8 as a downstream transcriptional target of Ras required for tumor angiogenesis\",\n      \"pmids\": [\"15542429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CXCL8 (IL-8) acts as an autocrine growth factor for NSCLC lung cancer cells expressing both IL-8 and CXCR1/CXCR2; the mitogenic function is mediated predominantly by CXCR1 (not CXCR2), as shown by selective receptor-neutralizing antibodies. In SCLC cells (expressing receptors but not producing IL-8), exogenous IL-8 stimulated proliferation in a dose-dependent manner.\",\n      \"method\": \"Anti-IL-8 neutralizing antibody, anti-CXCR1 and anti-CXCR2 antibodies, MTT proliferation assay, PCNA analysis, cell cycle analysis\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific functional attribution using selective neutralizing antibodies in multiple cell lines with multiple proliferation readouts\",\n      \"pmids\": [\"15545974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"2-Arylpropionic acid compounds (including repertaxin) are noncompetitive CXCL8 inhibitors that bind an allosteric site within the transmembrane (TM) region of CXCR1. The binding site was confirmed by alanine scanning mutagenesis and photoaffinity labeling of CXCR1.\",\n      \"method\": \"Molecular modeling, alanine scanning mutagenesis of CXCR1, photoaffinity labeling, PMN chemotaxis inhibition assay\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus covalent photolabeling identifying receptor binding site; orthogonal methods\",\n      \"pmids\": [\"15974585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Thrombin induces IL-8/CXCL8 expression in human lung epithelial cells (A549) through PAR1 and PAR4 receptors via a phosphoinositide-PLC/PKCα/c-Src/IKKαβ signaling cascade leading to NF-κB activation. PKCα, c-Src, and IKKαβ form a physical complex, and the CXCL8 NF-κB κB site is required for thrombin-induced transcription.\",\n      \"method\": \"Dominant-negative mutants, pharmacological inhibitors (U73122, Ro-32-0432, Bay 117082), κB-site luciferase reporter, Co-immunoprecipitation (PKCα/c-Src/IKKαβ complex), kinase activity assays, NF-κB EMSA\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissected by dominant-negatives, multiple pharmacological inhibitors, Co-IP of complex, and promoter reporter with site-directed mutation\",\n      \"pmids\": [\"16920985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Murine CXCR1 is a functional receptor that binds and responds to human IL-8/CXCL8 and mouse/human GCP-2/CXCL6, but not to CXCR2-selective ligands (ENA-78, NAP-2, GRO-α/β/γ, CINC-1-3). Functional characterization included GTPγS exchange and chemotaxis of mCXCR1-transfected cells.\",\n      \"method\": \"Receptor transfection, radioligand binding, GTPγS exchange assay, chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted receptor pharmacology in transfected cells with multiple functional readouts\",\n      \"pmids\": [\"17197447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Peptidylarginine deiminase (PAD) citrullinates CXCL8 at Arg5, generating CXCL8(1-77)Cit5. This modification: (i) reduces GAG affinity, (ii) reduces CXCR2-dependent Ca²⁺ signaling and ERK1/2 phosphorylation, (iii) confers resistance to thrombin/plasmin-dependent N-terminal processing to the more potent CXCL8(6-77) form, and (iv) abolishes neutrophil recruitment in vivo despite retained in vitro chemotactic activity.\",\n      \"method\": \"PAD citrullination in vitro, mass spectrometry identification of Cit5 on natural leukocyte CXCL8, GAG binding assay, Ca²⁺ signaling, ERK phosphorylation, thrombin/plasmin cleavage assay, in vivo peritoneal neutrophil recruitment, rabbit cornea angiogenesis assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — PTM identified on natural protein, reconstituted biochemically, validated across receptor signaling, proteolytic processing resistance, and in vivo animal models\",\n      \"pmids\": [\"18710930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL8 promotes invasiveness and angiogenesis in pancreatic cancer through HUVEC proliferation/invasion and tube formation via paracrine signaling. Fibroblast-derived CXCL12 enhances CXCL8 production by PaCa cells, and PaCa-derived CXCL8 enhances CXCL12 production in fibroblasts, establishing a cooperative tumor-stromal loop.\",\n      \"method\": \"Co-culture systems, ELISA, Matrigel invasion assay, MTS proliferation assay, HUVEC tube formation assay, CXCR4/CXCR2 expression by RT-PCR\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-culture mechanistic experiments demonstrating bi-directional paracrine loop, single lab\",\n      \"pmids\": [\"19035451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cell surface-bound IL-1α is an upstream regulator of senescence-associated IL-8/CXCL8 secretion in human fibroblasts. IL-1 receptor antagonist, neutralizing IL-1α antibodies, and IL-1α RNAi all suppressed senescence-associated IL-8 secretion. This pathway operates through IL-1R/IRAK1 → NF-κB/C/EBPβ → IL-8 transcription.\",\n      \"method\": \"RNAi knockdown, neutralizing antibodies, IL-1R antagonist, NF-κB DNA-binding assay, IRAK1 depletion, conditioned medium tumor invasion assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic and pharmacological perturbations defining upstream regulator of CXCL8 in senescence\",\n      \"pmids\": [\"19805069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MiR-146a/b are induced during cellular senescence and function as negative regulators of senescence-associated IL-6 and IL-8 secretion by downregulating IRAK1, a key IL-1R signaling component. Ectopic miR-146a/b expression in primary fibroblasts suppressed IL-6 and IL-8 secretion.\",\n      \"method\": \"miRNA profiling, ectopic miRNA expression, IRAK1 knockdown, ELISA for IL-6/IL-8, IL-1α neutralizing antibodies\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ectopic gain-of-function and epistasis (IL-1α blockade abolishing miR-146a/b and IL-8) with mechanistic IRAK1 linkage\",\n      \"pmids\": [\"20148189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Glycosaminoglycan-mediated CXCL8 binding to endothelial cells induces downstream signaling (identified syndecan-4/SDC4 as a potential proteoglycan co-receptor) and changes in cytoskeletal organization proteins (Zyxin, Caldesmon), demonstrating a GAG-dependent signaling pathway distinct from CXCR1/CXCR2-mediated neutrophil signaling.\",\n      \"method\": \"Gene array, RT-PCR, flow cytometry (SDC4), enzymatic GAG depolymerization (heparinase III, chondroitinase ABC), proteomic analysis of endothelial protein expression changes\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, proteomics plus enzymatic depletion, moderate mechanistic depth\",\n      \"pmids\": [\"29207576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL8 promotes endothelial cell migration through a heparan sulfate (HS)-dependent mechanism: removal of HS by heparinase III abolished CXCL8-induced wound healing, suppressed CXCL8-upregulated Cdc42, Rac1, and RhoA activity, and blocked actin polymerization, polarization, and stress fiber formation.\",\n      \"method\": \"Wound healing assay, heparinase III enzymatic HS removal, Rho GTPase activity assays (Cdc42, Rac1, RhoA), actin cytoskeleton imaging\",\n      \"journal\": \"PeerJ\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic HS removal with defined molecular readouts of Rho GTPase and cytoskeletal responses; single lab\",\n      \"pmids\": [\"26870616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TSG-6 directly binds CXCL8 at its glycosaminoglycan-binding site (Kd ~25 nM), antagonizing CXCL8 association with heparin, impairing CXCL8 binding to cell-surface GAGs, blocking CXCL8 transcytosis across endothelial monolayers, and suppressing CXCL8-mediated neutrophil chemotaxis. TSG-6 is identified as the first soluble mammalian chemokine-binding protein.\",\n      \"method\": \"SPR binding (Kd measurement), heparin competition assay, transendothelial migration assay, cell-surface GAG binding assay, transwell chemotaxis assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding affinity measurement plus multiple functional assays demonstrating mechanism of inhibition\",\n      \"pmids\": [\"24501198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MiR-146a limits CXCL8/CXCL1-driven inflammation after renal ischemia-reperfusion injury via suppression of IRAK1. In miR-146a-/- mice, IRI caused more tubular injury, inflammatory infiltrates, and fibrosis; overexpression/knockdown of miR-146a in tubular cells inversely regulated IRAK1 and CXCL8/CXCL1. CXCL8/CXCL1 signaling inhibition rescued the miR-146a-/- phenotype.\",\n      \"method\": \"miR-146a knockout mice, unilateral IRI model, in vitro miRNA overexpression/knockdown, CXCL8 pathway inhibition rescue, IRAK1 expression analysis\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological rescue with CXCL8 pathway inhibition; in vivo and in vitro orthogonal approaches\",\n      \"pmids\": [\"27444565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZO-1 (zonula occludens-1), when relocalized from tight junctions to the cytonuclear compartment, activates CXCL8/IL-8 transcription through a specific 173-bp promoter region containing a critical NF-κB (p65) site. ZO-1 overexpression promotes angiogenesis in ex vivo and in vivo assays, and NSCLC with cytonuclear ZO-1 was significantly more angiogenic.\",\n      \"method\": \"siRNA/cDNA transfection, luciferase reporter assay with promoter truncations and κB site mutation, p65 siRNA, IκBα/p65 phosphorylation analysis, ex vivo/in vivo angiogenesis assays\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter dissection with site-directed mutation plus genetic epistasis (p65 knockdown) and functional angiogenesis assays\",\n      \"pmids\": [\"28057697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Citrullination of CXCL8 at Arg5 and N-terminal truncation to CXCL8(6-77) differentially modulate CXCR1 and CXCR2 internalization, Gαi-dependent signaling, and β-arrestin 1/2 recruitment. CXCL8(6-77) shows enhanced β-arrestin 2 recruitment to both CXCR1 and CXCR2; [Cit5]CXCL8 enhances β-arrestin 2 recruitment specifically to CXCR2. Neither modification acts as a biased agonist (no shift in G-protein vs. β-arrestin preference).\",\n      \"method\": \"Synthetic CXCL8 variants, neutrophil receptor internalization assays, Gαi signaling (HTRF), β-arrestin 1/2 recruitment assays (BRET)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemically defined synthetic variants with quantitative receptor signaling assays distinguishing G-protein and β-arrestin pathways\",\n      \"pmids\": [\"30486423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Evasin-3 (a tick salivary protein) binds CXCL8 and disrupts both the GAG-binding site and the CXCR2 interaction surface of CXCL8, as revealed by solution NMR. Synthetic Evasin-3 variants (linear and cyclic peptides) bound CXCL8 with Kd ~13–27 nM and effectively inhibited CXCL8-induced PMN migration.\",\n      \"method\": \"Solution NMR structure of CXCL8–Evasin-3 complex, SPR binding assays, PMN chemotaxis inhibition assay, solid-phase peptide synthesis of truncated variants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure of protein-protein complex with SPR quantification and functional validation\",\n      \"pmids\": [\"31235521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Notch1 activation in triple-negative breast cancer cells, driven by contact with MSCs or CAFs in a TNFα/IL-1β-inflammatory context, leads to NF-κB (p65) activation which in turn upregulates CXCL8 production in TNBC cells. Notch1 siRNA and DAPT (γ-secretase inhibitor) suppressed contact-dependent CXCL8 induction and TNBC migration/invasion.\",\n      \"method\": \"Notch1 siRNA, CRISPR/Cas9 p65 knockdown, CXCL8 siRNA, γ-secretase inhibitor (DAPT), co-culture contact vs. non-contact conditions, migration/invasion assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic tools (siRNA, CRISPR) and pharmacological inhibitor with defined functional readouts in structured co-culture system\",\n      \"pmids\": [\"31105691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"N-terminal truncation of CXCL8 to generate CXCL8(9-77) potentiates actin polymerization in neutrophils and significantly enhances in vivo neutrophil recruitment to the mouse peritoneal cavity compared to CXCL8(6-77), while Ca²⁺ signaling and in vitro chemotaxis potency are comparable between truncated forms.\",\n      \"method\": \"Actin polymerization assay, Ca²⁺ signaling, in vitro chemotaxis, in vivo peritoneal recruitment model, neutrophil surface marker assays (CD62L, CD11a/b, CD15), degranulation assay, phagocytosis assay\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct comparison of defined natural truncation variants across multiple assays including in vivo model\",\n      \"pmids\": [\"32272490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Thrombin activates a DCLK1/RhoA/YAP signaling cascade in lung epithelial cells to induce CXCL8 expression. DCLK1 (activated via ERK) activates RhoA and promotes YAP dephosphorylation at Ser127 and nuclear translocation; nuclear YAP forms a complex with p65 (NF-κB) and both are recruited to the NF-κB site on the CXCL8 promoter. DCLK1 siRNA blocked RhoA, YAP activation, κB-luciferase activity, and p65/YAP promoter binding.\",\n      \"method\": \"siRNA (DCLK1, YAP), pharmacological inhibitors (DCLK1, ERK), ChIP assay (YAP and p65 at IL-8 promoter), luciferase reporter, Western blot (pSer127-YAP), immunofluorescence (YAP localization), ELISA, in vivo asthma model (OVA-induced)\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming promoter occupancy plus multiple genetic/pharmacological epistasis experiments in vitro and in vivo validation\",\n      \"pmids\": [\"36369000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL8 maintains the mesenchymal state of glioblastoma stem cells (GSCs) via cell-intrinsic PI3K/AKT and NF-κB signaling, and drives M2-like TAM polarization through a cell-extrinsic CXCR2-JAK2/STAT3 axis. Combined genetic/pharmacological inhibition of these dual pathways suppressed GBM tumor growth and prolonged survival in orthotopic xenograft models.\",\n      \"method\": \"Patient-derived GSC cultures, xenograft model, multi-omics RNA-seq, genetic inhibition (CXCL8/CXCR2 knockdown), small molecule inhibitors, TAM polarization assays, PI3K/AKT and JAK2/STAT3 pathway analysis\",\n      \"journal\": \"Clinical cancer research : an official journal of the American Association for Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual cell-intrinsic and extrinsic pathway dissection with genetic and pharmacological tools, validated in vivo\",\n      \"pmids\": [\"37439870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL8/CXCR2 signaling mediates bone marrow fibrosis in myelofibrosis: hematopoietic stem/progenitor cells from MF patients display enriched CXCL8/CXCR2 signatures. Genetic deletion of Cxcr2 in a murine MF model abrogated fibrosis and extended survival; pharmacological CXCR1/2 inhibition attenuated fibrosis and synergized with JAK inhibitor therapy.\",\n      \"method\": \"Single-cell transcriptomics, cytokine secretion studies, Cxcr2 genetic knockout in adoptive transfer model, pharmacological CXCR1/2 inhibition, in vitro HSC proliferation assay with CXCL8\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO in disease model plus pharmacological synergy study with mechanistic single-cell resolution\",\n      \"pmids\": [\"36800567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL8 (IL-8) is a dimeric CXC chemokine (NMR structure resolved) secreted by monocytes, macrophages, and epithelial cells in response to IL-1, TNF, LPS, and Ras oncogene signaling via NF-κB and related transcription factors; it is processed from a 99-aa precursor, and its activity is fine-tuned by N-terminal proteolytic truncation (MMP-9 generating the more potent CXCL8(7-77)) and citrullination at Arg5 by PAD, which reduces GAG binding and CXCR2 signaling; mature CXCL8 is transcytosed across venular endothelium for luminal presentation via its GAG-binding C-terminus, and signals through two GPCRs—CXCR1 (IL-8-selective) and CXCR2 (promiscuous)—via Gαi/Ca²⁺, PI3K/AKT, ERK, and β-arrestin pathways to drive neutrophil chemotaxis, actin polymerization, degranulation, and respiratory burst; additionally, CXCL8 promotes angiogenesis by directly stimulating endothelial cell survival, proliferation, MMP-2/9 production, and tube formation predominantly through CXCR2, and mediates tumor progression through autocrine growth factor activity, cancer stem cell maintenance (PI3K/AKT and NF-κB), and immunosuppressive TAM polarization (CXCR2-JAK2/STAT3).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CXCL8 is a CXC chemokine that functions as a central mediator of neutrophil recruitment, angiogenesis, and tumor microenvironment remodeling through signaling via the G protein-coupled receptors CXCR1 and CXCR2. CXCL8 binds high-affinity receptors on neutrophils to activate Gαi, β-arrestin, p38 MAPK, PI3K/AKT, and Rho GTPase pathways, while its interaction with heparan sulfate proteoglycans (including syndecan-4) on endothelial cells is required for haptotactic gradient formation, Rho GTPase activation, and endothelial migration [PMID:2647892, PMID:30486423, PMID:26870616, PMID:29207576]. CXCL8 bioactivity is fine-tuned by post-translational modifications: PAD-mediated citrullination at Arg-5 reduces glycosaminoglycan affinity and abolishes neutrophil extravasation in vivo, while NH₂-terminal truncation to CXCL8(9-77) potentiates actin polymerization and in vivo neutrophil recruitment [PMID:18710930, PMID:32272490, PMID:30486423]. Transcriptionally, CXCL8 is driven by NF-κB—activated through thrombin/PAR1/PKCα/c-Src/IKK, DCLK1/RhoA/YAP/p65, and Notch1 pathways—and suppressed by KLF4 promoter binding; in tumors, autocrine and paracrine CXCL8/CXCR2 signaling sustains cancer stem cell self-renewal via PI3K/AKT, promotes angiogenesis, drives M2 macrophage polarization through JAK2/STAT3, induces PD-L1 expression to suppress CD8⁺ T cells, and mediates bone marrow fibrosis in myeloproliferative neoplasms [PMID:16920985, PMID:36369000, PMID:34038586, PMID:37439870, PMID:36800567, PMID:37665572].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing that CXCL8 signals through dedicated, high-affinity cell-surface receptors resolved how this chemokine selectively activates neutrophils despite the presence of multiple chemoattractant systems.\",\n      \"evidence\": \"Radioligand binding with Scatchard analysis and chemical crosslinking on human neutrophils identified two receptor polypeptides (~67 and ~59 kDa) with Kd ~0.8 nM\",\n      \"pmids\": [\"2647892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the two receptor species not yet cloned\", \"Downstream signaling cascades uncharacterized\", \"Relative functional roles of the two receptor types unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Mapping the CXCL8 gene to chromosome 4q12-q21 within a CXC chemokine cluster established its genomic context and provided the basis for understanding coordinate regulation of related chemokines.\",\n      \"evidence\": \"Somatic cell hybrid mapping and in situ hybridization combined with exon-intron structure determination\",\n      \"pmids\": [\"1967588\", \"2200751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter regulatory elements not yet defined\", \"Relationship between genomic clustering and co-regulation not demonstrated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that CXCL8/CXCR2 signaling drives chondrocyte hypertrophic differentiation via p38 MAPK and transglutaminase 2 expanded CXCL8 biology beyond immune cell chemotaxis into skeletal development.\",\n      \"evidence\": \"Primary chondrocyte cultures with CXCR2 ligands, p38 inhibitors, and TG2-knockout mouse chondrocytes\",\n      \"pmids\": [\"14530367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXCL8 acts directly on chondrocytes in vivo during development not shown\", \"Mechanism by which TG2 transduces the CXCR2 signal unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identifying CXCL8 as an autocrine growth factor for NSCLC acting primarily through CXCR1 established receptor-specific mitogenic roles distinct from its canonical neutrophil chemotactic function.\",\n      \"evidence\": \"Receptor-specific neutralizing antibody blockade with proliferation and cell cycle readouts in NSCLC cells\",\n      \"pmids\": [\"15545974\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CXCR1-specific downstream mitogenic signaling pathway not delineated\", \"In vivo relevance of CXCR1-selective autocrine loop not tested\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping the allosteric inhibitor binding site within CXCR1 transmembrane helices provided the first structural pharmacology framework for non-competitive CXCL8 signaling blockade.\",\n      \"evidence\": \"Alanine scanning mutagenesis and photoaffinity labeling of CXCR1 with repertaxin and ketoprofen, validated by neutrophil chemotaxis\",\n      \"pmids\": [\"15974585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full receptor structure not determined\", \"Whether allosteric mechanism applies to CXCR2 not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Delineation of the thrombin→PAR1/4→PKCα/c-Src/IKK→NF-κB→CXCL8 promoter cascade resolved how the coagulation system drives CXCL8 transcription in lung epithelium, while identification of mouse CXCR1 as a functional CXCL8 receptor validated cross-species signaling.\",\n      \"evidence\": \"Dominant-negative c-Src, pharmacological inhibitors, NF-κB promoter-luciferase with κB-site mutation, co-IP of PKCα/c-Src/IKKαβ in epithelial cells; GTPγS exchange, binding and chemotaxis assays for mCXCR1 in transfected cells\",\n      \"pmids\": [\"16920985\", \"17197447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this coagulation-CXCL8 axis operates in non-epithelial cell types unclear\", \"mCXCR1 ligand selectivity mechanism at structural level undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that PAD-mediated citrullination at Arg-5 uncouples CXCL8 chemotactic potency in vitro from neutrophil extravasation in vivo revealed post-translational modification as a master switch controlling CXCL8 bioavailability through GAG affinity modulation.\",\n      \"evidence\": \"Identification of natural citrullinated CXCL8 from leukocytes, GAG binding assays, calcium flux, ERK phosphorylation, in vivo peritoneal neutrophil recruitment and corneal angiogenesis\",\n      \"pmids\": [\"18710930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PAD isoform responsible in vivo not identified\", \"Stoichiometry of citrullination under physiological inflammation unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration that tumor-derived CXCL8 promotes endothelial proliferation and tube formation via paracrine CXCR2 signaling established CXCL8 as a direct pro-angiogenic chemokine in the tumor microenvironment.\",\n      \"evidence\": \"ELISA, Matrigel invasion, HUVEC tube formation in pancreatic cancer co-culture systems\",\n      \"pmids\": [\"19035451\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of CXCL8 versus other CXC ligands to tumor angiogenesis not quantified\", \"In vivo angiogenesis blockade by selective CXCL8 neutralization not performed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Multiple studies converged to show that CXCL8 function requires heparan sulfate engagement for Rho GTPase activation and endothelial migration, that ZO-1 delocalization activates CXCL8 transcription, and that Thy-1/CD18 adhesion triggers autocrine CXCL8 release from neutrophils—expanding the understanding of both CXCL8 signal transduction and transcriptional regulation.\",\n      \"evidence\": \"Heparinase III removal of HS with Rho GTPase and migration assays; ZO-1 siRNA/overexpression with CXCL8 promoter-luciferase; Thy-1/CD18 blocking antibodies with ELISA\",\n      \"pmids\": [\"26870616\", \"22064657\", \"18389476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific GAG sulfation patterns required for CXCL8 signaling not defined\", \"Mechanism of ZO-1 nuclear translocation and promoter activation unclear\", \"Whether Thy-1/CD18 CXCL8 release is vesicular or de novo synthesis not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linking Met receptor signaling to CXCL8 secretion and paracrine tumor angiogenesis established CXCL8 as a key effector through which oncogenic RTK signaling remodels the tumor vasculature.\",\n      \"evidence\": \"Met RNAi knockdown with ELISA for CXCL8 and orthotopic pancreatic tumor model\",\n      \"pmids\": [\"22815748\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors downstream of Met that drive CXCL8 not identified\", \"Whether other Met-dependent chemokines contribute not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of TSG-6 as a soluble chemokine-binding protein that sequesters CXCL8 from GAGs and blocks transcytosis defined a new class of endogenous CXCL8 regulatory mechanism.\",\n      \"evidence\": \"Direct binding assay (KD ~25 nM), heparin competition, transendothelial migration assay, in vivo neutrophil recruitment\",\n      \"pmids\": [\"24501198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TSG-6 regulates other CXC chemokines with similar potency not tested\", \"In vivo stoichiometry and tissue contexts of TSG-6/CXCL8 interaction unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"ChIP-validated KLF4 binding to the CXCL8 promoter identified the first transcriptional repressor, and its reciprocal downregulation by CXCL8 revealed a positive feedback loop exploited in H. pylori–associated gastric carcinogenesis.\",\n      \"evidence\": \"ChIP for KLF4 at CXCL8 promoter, KLF4 knockdown/overexpression, H. pylori CagA transduction, in vivo tumor growth\",\n      \"pmids\": [\"34038586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CXCL8 reduces KLF4 protein not defined\", \"Whether other KLF family members compensate at the CXCL8 promoter unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that ZO-1 activates CXCL8 specifically through NF-κB p65 binding to a 173-bp promoter region, and that syndecan-4 serves as an endothelial GAG co-receptor, refined both transcriptional and cell-surface signaling mechanisms.\",\n      \"evidence\": \"Mutated CXCL8 promoter-luciferase, p65 silencing, IκBα/p65 phosphorylation analysis, in vivo angiogenesis; flow cytometry for SDC4, enzymatic GAG depolymerization with proteomic analysis\",\n      \"pmids\": [\"28057697\", \"29207576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SDC4 interaction with CXCL8 not confirmed by binding assay\", \"Whether ZO-1 physically associates with NF-κB components not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Systematic comparison of citrullinated and NH₂-truncated CXCL8 variants showed that both modifications enhance Gαi signaling and β-arrestin recruitment without inducing biased agonism, clarifying how post-translational processing tunes receptor engagement without switching signaling mode.\",\n      \"evidence\": \"Chemically synthesized CXCL8 variants tested for receptor internalization, β-arrestin recruitment, and Gαi signaling on human neutrophils\",\n      \"pmids\": [\"30486423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for enhanced β-arrestin recruitment by truncated forms not resolved\", \"In vivo relevance of β-arrestin pathway enhancement not assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Structural determination of the CXCL8–Evasin-3 complex by NMR revealed how an exogenous protein neutralizes CXCL8 by occluding both the GAG-binding site and the CXCR2 interface, while Notch1 was identified as a transcriptional activator downstream of NF-κB in tumor–stroma contact, and CXCL8/CXCR2 was linked to PD-L1 induction on tumor-associated macrophages.\",\n      \"evidence\": \"NMR structure of Evasin-3/CXCL8 complex with SPR binding and neutrophil chemotaxis; Notch1/CXCL8/p65 siRNA and CRISPR in TNBC co-cultures; CXCR2 inhibitor reparixin with flow cytometry in gastric cancer tissue\",\n      \"pmids\": [\"31235521\", \"31105691\", \"30661053\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous mammalian proteins mimic Evasin-3 mechanism unknown\", \"Notch1 binding at the CXCL8 promoter not directly tested by ChIP\", \"Mechanism linking CXCR2 to PD-L1 transcription not fully defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that further NH₂-terminal truncation to CXCL8(9-77) potentiates actin polymerization and in vivo neutrophil recruitment beyond CXCL8(6-77) established a graded processing hierarchy controlling chemokine potency.\",\n      \"evidence\": \"Comparison of natural CXCL8 isoforms in actin polymerization, calcium signaling, surface marker expression, and in vivo murine peritoneal recruitment\",\n      \"pmids\": [\"32272490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease(s) generating CXCL8(9-77) in vivo not identified\", \"Whether CXCL8(9-77) has altered GAG or receptor binding kinetics not measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of the DCLK1→RhoA→YAP/p65 complex at the CXCL8 promoter added a mechanotransduction-responsive transcriptional arm, while radiation-induced senescence-associated CXCL8 secretion was shown to recruit NK cells, revealing context-dependent immune consequences.\",\n      \"evidence\": \"ChIP for YAP/p65 at CXCL8 promoter with DCLK1/RhoA siRNA in epithelial cells; NF-κB/mTOR inhibitors and adoptive NK transfer in irradiated xenografts\",\n      \"pmids\": [\"36369000\", \"35319989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YAP acts as a direct transcriptional co-activator or scaffold at the CXCL8 promoter not distinguished\", \"Relative contribution of CXCL8 versus other SASP factors to NK recruitment unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Convergent studies established CXCL8/CXCR2 as a driver of bone marrow fibrosis in myeloproliferative neoplasms, an autocrine stem cell maintenance factor in glioblastoma via PI3K/AKT and NF-κB, and a STAT3-dependent inducer of immunosuppressive M2 macrophage polarization in colorectal cancer.\",\n      \"evidence\": \"Cxcr2 genetic deletion in murine MPLW515L model with survival endpoint; patient-derived GSC xenografts with dual pathway inhibition; STAT3 signaling analysis with murine CRC model\",\n      \"pmids\": [\"36800567\", \"37439870\", \"37665572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-intrinsic versus microenvironment contributions of CXCR2 in myelofibrosis not fully separated\", \"Whether CXCL8 autocrine signaling in GSCs is CXCR1- or CXCR2-dependent not resolved\", \"Upstream signals initiating CXCL8 overproduction in MPN stem cells undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full structural basis of CXCL8 receptor selectivity between CXCR1 and CXCR2, the identity of proteases generating potent NH₂-truncated isoforms in vivo, and how the transcriptional and post-translational regulatory circuits integrate in different inflammatory and neoplastic tissue contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full CXCL8–CXCR1 or CXCL8–CXCR2 co-structure available\", \"In vivo protease responsible for CXCL8(9-77) generation not identified\", \"Quantitative integration of PAD citrullination, NH₂-truncation, and GAG binding in tissue-specific contexts not modeled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 4, 8, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 22, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 7, 8, 12, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 7, 10, 16, 17, 22, 26, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 6, 9, 14, 19, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 8, 11, 20, 21, 23, 24, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CXCR1\",\n      \"CXCR2\",\n      \"TNFAIP6\",\n      \"SDC4\",\n      \"KLF4\",\n      \"RELA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CXCL8 (interleukin-8) is a prototypical ELR+ CXC chemokine that functions as the principal neutrophil chemoattractant and activator while simultaneously acting as a potent pro-angiogenic factor and autocrine tumor growth signal. Secreted by monocytes, macrophages, epithelial cells, and tumor cells in response to IL-1, TNF, LPS, thrombin, and oncogenic Ras—through NF-κB-dependent transcription regulated by upstream IL-1R/IRAK1, PAR1/PKCα/c-Src/IKK, DCLK1/RhoA/YAP–p65, and Notch1 pathways—CXCL8 signals through two GPCRs: the IL-8-selective CXCR1 and the promiscuous CXCR2, coupling to Gαi/Ca²⁺, PI3K/AKT, ERK, p38 MAPK, and β-arrestin to drive neutrophil chemotaxis, degranulation, respiratory burst, and endothelial cell survival, proliferation, and tube formation [PMID:3480540, PMID:1840701, PMID:8702798, PMID:1281554, PMID:12496258]. Its bioactivity is fine-tuned post-translationally: N-terminal truncation by MMP-9 generates the 10–27-fold more potent CXCL8(7-77), whereas citrullination at Arg5 by peptidylarginine deiminase reduces GAG binding, CXCR2 signaling, and in vivo neutrophil recruitment [PMID:11023497, PMID:18710930, PMID:30486423]. CXCL8 is transcytosed across venular endothelium via its GAG-binding C-terminus for luminal presentation to leukocytes, a process antagonized by TSG-6 binding [PMID:9363947, PMID:24501198]. In cancer, CXCL8 sustains glioblastoma stem cell mesenchymal identity through PI3K/AKT and NF-κB, polarizes tumor-associated macrophages via CXCR2–JAK2/STAT3, and drives myelofibrosis through CXCR2-dependent hematopoietic stem cell expansion and bone marrow fibrosis [PMID:37439870, PMID:36800567].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"The discovery of CXCL8 as a distinct neutrophil-specific chemoattractant produced by LPS-stimulated monocytes established it as a novel mediator separate from complement factors and lipid mediators, answering the question of what soluble factor selectively recruits neutrophils during inflammation.\",\n      \"evidence\": \"Purification to homogeneity from monocyte conditioned medium with chemotaxis assays showing neutrophil but not monocyte activity\",\n      \"pmids\": [\"3480540\", \"3322281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown\", \"In vivo relevance not yet established\", \"Gene structure not yet determined\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Molecular cloning of the CXCL8 cDNA revealed a 99-amino-acid precursor with signal peptide processing and rapid mRNA induction by IL-1, TNF, and LPS but not interferons, establishing CXCL8 as an immediate-early inflammatory gene with defined transcriptional inducers.\",\n      \"evidence\": \"cDNA cloning from LPS-stimulated monocytes with Northern blot kinetics of mRNA induction\",\n      \"pmids\": [\"3260265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements responsible for inducibility not yet mapped\", \"Post-translational processing details unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of high-affinity CXCL8-binding receptors on neutrophils (~20,000 sites/cell, Kd ~0.8 nM) distinct from all known chemoattractant receptors, together with demonstration that CXCL8 also attracts T lymphocytes in vivo, expanded the target cell repertoire and established receptor-mediated signaling as the basis for CXCL8 activity.\",\n      \"evidence\": \"Radioligand binding, Scatchard analysis, chemical cross-linking on neutrophils; in vivo rat intradermal injection with lymphocyte/neutrophil quantification\",\n      \"pmids\": [\"2647892\", \"2648569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of receptors unknown\", \"Signaling pathways downstream of binding not characterized\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Determination of the CXCL8 dimer structure by NMR and mapping of the gene to chromosome 4q12–q21 within the CXC chemokine cluster provided the structural and genomic framework, revealing the antiparallel α-helix/β-sheet architecture and its evolutionary relationship to the PF4 superfamily.\",\n      \"evidence\": \"NMR spectroscopy with 1880 distance restraints; somatic cell hybrid mapping and in situ hybridization\",\n      \"pmids\": [\"2184886\", \"1967588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Monomer vs. dimer activity not resolved\", \"Structure of receptor-bound CXCL8 unknown\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Cloning of CXCR1 (IL-8RA) as a GPCR with high-affinity IL-8 binding and calcium mobilization in transfected cells answered the fundamental question of receptor identity and established the GPCR/Gαi signaling paradigm for CXCL8.\",\n      \"evidence\": \"Expression cloning from neutrophil cDNA library, radioligand binding and calcium flux in transfected mammalian cells\",\n      \"pmids\": [\"1840701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Second receptor (CXCR2) selectivity profile not yet defined\", \"Downstream signaling cascades not mapped\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"The demonstration that CXCL8 is a potent angiogenic factor—inducing endothelial proliferation, chemotaxis, and neovascularization in the rat cornea—revealed a second major biological function beyond neutrophil chemotaxis.\",\n      \"evidence\": \"Rat cornea angiogenesis assay, HUVEC proliferation/chemotaxis, anti-IL-8 antibody and antisense oligonucleotide blockade\",\n      \"pmids\": [\"1281554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor subtype mediating angiogenesis unknown\", \"Signaling pathways in endothelial cells not defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Pharmacological characterization of CXCR1 vs. CXCR2 selectivity resolved how CXCL8 signals through two receptors with distinct ligand profiles: CXCR1 is IL-8-selective while CXCR2 is promiscuous for ELR+ CXC chemokines.\",\n      \"evidence\": \"Quantitative calcium flux and competitive radioligand binding in HEK293 cells transfected with individual receptors\",\n      \"pmids\": [\"8702798\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor subtype-specific downstream effectors not dissected\", \"In vivo receptor subtype contributions unclear\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Discovery that CXCL8 is transcytosed across venular endothelium and presented luminally via its GAG-binding C-terminus resolved how a subendothelially produced chemokine reaches and activates intravascular leukocytes, establishing the transcytosis–immobilization paradigm for chemokine biology.\",\n      \"evidence\": \"Electron microscopy of transcytosis, C-terminal deletion mutants lacking GAG binding, in vivo leukocyte emigration assay\",\n      \"pmids\": [\"9363947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Vesicular machinery for transcytosis unidentified\", \"Proteoglycan identity on luminal surface unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of MMP-9-mediated N-terminal truncation generating the 10–27-fold more potent CXCL8(7-77) established a positive feedback amplification loop at inflammatory sites where neutrophil degranulation potentiates the chemokine that recruited them.\",\n      \"evidence\": \"In vitro MMP-9 cleavage with neutrophil Ca²⁺ flux, chemotaxis, degranulation, and receptor binding assays on CXCR1/CXCR2-transfected cells\",\n      \"pmids\": [\"11023497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo ratio of CXCL8 proteoforms during inflammation not quantified\", \"Other proteases generating truncated forms not systematically assessed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Attribution of CXCL8-driven angiogenesis specifically to CXCR2 (with ERK1/2 and PI3K as required effectors) in primary microvascular endothelial cells resolved which receptor subtype mediates the pro-angiogenic program.\",\n      \"evidence\": \"HIMEC expressing CXCR2 but not CXCR1; neutralizing antibodies, ERK and PI3K inhibitors blocking tube formation and chemotaxis\",\n      \"pmids\": [\"12496258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCR1 contribution to angiogenesis in other vascular beds not excluded\", \"Transcriptional targets downstream of ERK/PI3K in endothelial cells not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstration that oncogenic Ras drives CXCL8 transcription and that CXCL8 is required for Ras-dependent tumor angiogenesis and inflammation repositioned CXCL8 as a critical effector of oncogene-driven tumor progression, while receptor-specific studies showed CXCR1-mediated autocrine growth in lung cancer.\",\n      \"evidence\": \"Tumor xenograft rescue with ectopic CXCL8 in Ras-impaired cells; selective CXCR1/CXCR2 neutralizing antibodies in NSCLC proliferation assays\",\n      \"pmids\": [\"15542429\", \"15545974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor(s) linking Ras to CXCL8 promoter not fully defined\", \"Autocrine loop contribution vs. paracrine angiogenic role not separated in vivo\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that PAD-mediated citrullination at Arg5 dampens GAG binding, CXCR2 signaling, and in vivo neutrophil recruitment—while also blocking N-terminal truncation to more active forms—revealed a post-translational brake that fine-tunes CXCL8 bioactivity at inflamed sites.\",\n      \"evidence\": \"PAD citrullination in vitro, mass spectrometry of natural leukocyte CXCL8, GAG/receptor signaling assays, thrombin/plasmin resistance, in vivo peritoneal recruitment\",\n      \"pmids\": [\"18710930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological conditions controlling PAD access to CXCL8 unknown\", \"Relative abundance of citrullinated vs. unmodified CXCL8 in human disease tissues not quantified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of surface-bound IL-1α/IRAK1/NF-κB as the upstream cascade driving senescence-associated CXCL8 secretion, negatively regulated by miR-146a/b targeting IRAK1, linked CXCL8 to the senescence-associated secretory phenotype and its regulation by a microRNA feedback loop.\",\n      \"evidence\": \"IL-1Rα, neutralizing antibodies, and IL-1α/IRAK1 RNAi suppressed senescence-associated IL-8; ectopic miR-146a/b suppressed IL-8 via IRAK1 depletion\",\n      \"pmids\": [\"19805069\", \"20148189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other miRNAs directly targeting CXCL8 mRNA not systematically evaluated\", \"In vivo relevance of miR-146a–CXCL8 axis in aging tissues not established at this time\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of TSG-6 as a soluble antagonist that binds the CXCL8 GAG-binding site with nanomolar affinity and blocks transcytosis and neutrophil chemotaxis revealed a physiological counter-regulatory mechanism for CXCL8 presentation and activity.\",\n      \"evidence\": \"SPR (Kd ~25 nM), heparin competition, transendothelial transcytosis blockade, chemotaxis inhibition\",\n      \"pmids\": [\"24501198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of TSG-6-CXCL8 interaction in resolving inflammation not tested\", \"Whether TSG-6 antagonizes other CXC chemokines not systematically assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Quantitative dissection of how citrullination and N-terminal truncation modulate Gαi signaling vs. β-arrestin recruitment to CXCR1 and CXCR2 showed that these post-translational modifications alter signaling magnitude at each receptor without inducing biased agonism, refining the model of CXCL8 proteoform-specific signaling.\",\n      \"evidence\": \"Synthetic CXCL8 variants tested by HTRF (Gαi) and BRET (β-arrestin 1/2) with quantitative dose-response curves\",\n      \"pmids\": [\"30486423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of β-arrestin recruitment differences in vivo unknown\", \"Whether additional post-translational modifications (e.g. oxidation) alter bias not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapping of a DCLK1/RhoA/YAP–p65 transcriptional cascade driving CXCL8 expression in thrombin-stimulated epithelial cells, with ChIP confirming YAP and p65 co-occupancy at the CXCL8 NF-κB site, revealed a non-canonical mechanotransduction input to CXCL8 transcription.\",\n      \"evidence\": \"ChIP of YAP/p65 at IL-8 promoter, DCLK1 and YAP siRNA epistasis, κB-luciferase reporter, in vivo asthma model validation\",\n      \"pmids\": [\"36369000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YAP-p65 co-regulation of CXCL8 operates in cell types beyond lung epithelium not tested\", \"Contribution relative to canonical NF-κB activation unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstration that CXCL8 operates through dual cell-intrinsic (PI3K/AKT, NF-κB maintaining cancer stemness) and cell-extrinsic (CXCR2–JAK2/STAT3 polarizing immunosuppressive TAMs) axes in glioblastoma, and that CXCL8/CXCR2 signaling drives bone marrow fibrosis in myelofibrosis, broadened the disease-relevant roles of CXCL8 beyond solid tumor angiogenesis.\",\n      \"evidence\": \"Patient-derived GSC xenografts with CXCL8/CXCR2 knockdown and combined pathway inhibition; Cxcr2 KO in murine MF model with pharmacological CXCR1/2 inhibition synergizing with JAK inhibitor\",\n      \"pmids\": [\"37439870\", \"36800567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of autocrine vs. paracrine CXCL8 in GBM microenvironment not fully resolved\", \"Whether CXCR1 contributes to MF pathology independently of CXCR2 not tested\", \"Clinical efficacy of CXCR2 inhibition in myelofibrosis awaits trial data\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CXCL8 binding to CXCR1 vs. CXCR2 at atomic resolution, the identity of the vesicular machinery mediating CXCL8 transcytosis, the quantitative proteoform landscape of CXCL8 at inflammatory sites in vivo, and whether therapeutic CXCL8 neutralization or receptor blockade can be safely deployed without compromising host defense.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of CXCL8–CXCR1 or CXCL8–CXCR2 complex available\", \"Transcytosis vesicle identity and regulatory machinery undefined\", \"Relative proteoform abundances in human disease tissues not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 9, 10, 14, 18, 36]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 2, 12, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 9, 12, 13, 22, 28, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [8, 11, 14, 20, 31, 35, 36]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 10, 12, 13, 22, 29, 34, 37]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [12, 27, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [17, 18, 23, 36, 37]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CXCR1\",\n      \"CXCR2\",\n      \"TNFAIP6\",\n      \"SDC4\",\n      \"MMP9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}